1
|
Giunta EF, Brighi N, Gurioli G, Matteucci F, Paganelli G, De Giorgi U. 177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers. Cancer Treat Rev 2024; 125:102699. [PMID: 38422894 DOI: 10.1016/j.ctrv.2024.102699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 02/14/2024] [Accepted: 02/16/2024] [Indexed: 03/02/2024]
Abstract
177Lu-PSMA has been approved for the treatment of PSMA-positive metastatic castration-resistant (mCRPC) patients who progressed to androgen receptor pathway inhibitors (ARPIs) and taxane-based chemotherapy. However, a higher proportion of patients do not respond to this type of radioligand therapy (RLT). To date, there is a lack of validated prognostic and predictive biomarkers for 177Lu-PSMA therapy in prostate cancer. Several studies have investigated the prognostic and predictive role of clinical and molecular factors and also the metabolic features of PET imaging. In this review, we aim to take stock of the current scenario, focusing on new emerging data from retrospective/prospective series and clinical trials. Given the high costs and the possibility of primary resistance, it seems essential to identify clinical and molecular characteristics that could allow clinicians to choose the right patient to treat with 177Lu-PSMA. Biomarker-based clinical trials are urgently needed in this field.
Collapse
Affiliation(s)
- Emilio Francesco Giunta
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
| | - Nicole Brighi
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Giorgia Gurioli
- Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Federica Matteucci
- Nuclear Medicine Operative Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Giovanni Paganelli
- Nuclear Medicine Operative Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Ugo De Giorgi
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| |
Collapse
|
2
|
Gennari A, Brain E, De Censi A, Nanni O, Wuerstlein R, Frassoldati A, Cortes J, Rossi V, Palleschi M, Alberini JL, Matteucci F, Piccardo A, Sacchetti G, Ilhan H, D'Avanzo F, Ruffilli B, Nardin S, Monti M, Puntoni M, Fontana V, Boni L, Harbeck N. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET. Ann Oncol 2024:S0923-7534(24)00057-7. [PMID: 38423389 DOI: 10.1016/j.annonc.2024.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 01/15/2024] [Accepted: 02/20/2024] [Indexed: 03/02/2024] Open
Abstract
BACKGROUND 18F-FES PET/CT is considered an accurate diagnostic tool to determine whole-body endocrine responsiveness. In the ET-FES trial, we evaluated 18F-FES PET/CT as a predictive tool in ER+/HER2- metastatic breast cancer (MBC). METHODS Eligible patients underwent a 18F-FES PET/CT at baseline. Patients with SUV≥2 received single agent ET until PD; patients with SUV<2 were randomized to single agent ET (Arm A) or chemotherapy (CT) (Arm B). Primary objective was to compare the activity of first line ET versus CT in patients with 18F-FES SUV <2. RESULTS Overall, 147 patients were enrolled; 117 presented with 18F-FES SUV≥2 and received ET; 30 pts with SUV<2 were randomized to ET or CT. After a median follow up of 62.4 months, 104 patients (73.2%) had disease progression and 53 died (37.3%). Median PFS was 12.4 months (95%CI 3.1-59.6) in patients with SUV <2 randomised to Arm A versus 23.0 months (95%CI 7.7-30.0) in Arm B, (HR = 0.71, 95%CI 0.3 - 1.7); median PFS was 18.0 months (95%CI 11.2-23.1) in patients with SUV≥2 treated with ET. Median OS was 28.2 months (95%CI 14.2-NE) in patients with SUV <2 randomized to ET (Arm A) versus 52.8 months (95%CI 16.2-NE) in Arm B (CT). Median OS was not reached in patients with SUV≥2. 60-month OS rate was 41.6% (95%CI 10.4-71.1%) in Arm A, 42.0% (95%CI 14.0-68.2%) in Arm B and 59.6% (95%CI 48.6-69.0%) in patients with SUV≥2. In patients with SUV≥2, 60-months OS rate was 72.6% if treated with aromatase inhibitors versus 40.6% in case of fulvestrant or tamoxifen (p<0.005). CONCLUSIONS The ET-FES trial demonstrated that ER+/HER2- MBC patients are a heterogeneous population, with different levels of endocrine responsiveness based on 18F-FES CT/PET SUV.
Collapse
Affiliation(s)
- A Gennari
- Department of Traslational Medicine, University of Piemonte Orientale, Novara, Italy;; Division of Medical Oncology, Maggiore University Hospital, Novara, Italy.
| | - E Brain
- Department of Medical Oncology, Institut Curie - Hôpital René Huguenin, Saint-Cloud, France
| | - A De Censi
- Medical Oncology, E.O. "Ospedali Galliera, Genova, Italy
| | - O Nanni
- Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - R Wuerstlein
- Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany
| | - A Frassoldati
- Clinical Oncology, S. Anna University Hospital, Ferrara, Italy
| | - J Cortes
- International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona, Spain; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain
| | - V Rossi
- Division of Medical Oncology, Maggiore University Hospital, Novara, Italy
| | - M Palleschi
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - J L Alberini
- Nuclear Medicine Department Centre Georges-Francois Leclerc, Dijon Cedex, France
| | - F Matteucci
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo studio dei tumori (IRST)- Dino Amadori, Meldola, Italy
| | - A Piccardo
- Department of Nuclear Medicine, E.O. "Ospedali Galliera, Genova, Italy
| | - G Sacchetti
- Division of Nuclear Medicine Unit, Maggiore University Hospital, Novara, Italy
| | - H Ilhan
- Department of Nuclear Medicine, LMU University Hospital, Munich, Germany
| | - F D'Avanzo
- Division of Medical Oncology, Maggiore University Hospital, Novara, Italy
| | - B Ruffilli
- Department of Traslational Medicine, University of Piemonte Orientale, Novara, Italy
| | - S Nardin
- Medical Oncology Unit 1, IRCCS - Ospedale Policlinico San Martino, Genoa, Italy
| | - M Monti
- Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - M Puntoni
- Clinical and Epidemiological Research Unit, University Hospital of Parma, Parma, Italy
| | - V Fontana
- Department of Clinical Epidemiology, IRCSS Ospedale Policlinico San Martino, Genoa 20900, Italy
| | - L Boni
- Department of Clinical Epidemiology, IRCSS Ospedale Policlinico San Martino, Genoa 20900, Italy
| | - N Harbeck
- Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany
| |
Collapse
|
3
|
Krols S, Matteucci F, Van Hecke K, Caljon G, Jacobson KA, Van Calenbergh S. Dual N6/C7-Substituted 7-Deazapurine and Tricyclic Ribonucleosides with Affinity for G Protein-Coupled Receptors. ACS Med Chem Lett 2024; 15:81-86. [PMID: 38229744 PMCID: PMC10789135 DOI: 10.1021/acsmedchemlett.3c00427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 12/13/2023] [Accepted: 12/19/2023] [Indexed: 01/18/2024] Open
Abstract
Various purine-based nucleoside analogues have demonstrated unexpected affinity for nonpurinergic G protein-coupled receptors (GPCRs), such as opioid and serotonin receptors. In this work, we synthesized a small library of new 7-deazaadenosine and pyrazolo[3,4-d]pyrimidine riboside analogues, featuring dual C7 and N6 modifications and assessed their affinity for various GPCRs. During the course of the synthesis of 7-ethynyl pyrazolo[3,4-d]pyrimidine ribosides, we observed the formation of an unprecedented tricyclic nucleobase, formed via a 6-endo-dig ring closure. The synthesis of this tricyclic nucleoside was optimized, and the substrate scope for such cyclization was further explored because it might avail further exploration in the nucleoside field. From displacement experiments on a panel of GPCRs and transporters, combining C7 and N6 modifications afforded noncytotoxic nucleosides with micromolar and submicromolar affinity for different GPCRs, such as the 5-hydroxytryptamine (5-HT)2B, κ-opioid (KOR), and σ1/2 receptor. These results corroborate that the novel nucleoside analogues reported here are potentially useful starting points for the further development of modulators of GPCRs and transmembrane proteins.
Collapse
Affiliation(s)
- Simon Krols
- Laboratory
for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
| | - Federica Matteucci
- Laboratory
for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
| | - Kristof Van Hecke
- XStruct,
Department of Chemistry, Ghent University, Krijgslaan 281-S3, 9000 Ghent, Belgium
| | - Guy Caljon
- Laboratory
of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium
| | - Kenneth A. Jacobson
- Molecular
Recognition Section, Laboratory of Bioorganic Chemistry, National
Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, United States
| | - Serge Van Calenbergh
- Laboratory
for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
| |
Collapse
|
4
|
Bottoni G, Fiz F, Puntoni M, Matteucci F, Monti M, DeCensi A, Nanni O, Brain E, Alberini JL, Dib B, Sacchetti G, Trimboli P, Treglia G, Harbeck N, Sola S, Gennari A, Piccardo A. Diagnostic effectiveness of [ 18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study. Eur J Nucl Med Mol Imaging 2023; 50:2477-2485. [PMID: 36879065 DOI: 10.1007/s00259-023-06173-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Accepted: 02/24/2023] [Indexed: 03/08/2023]
Abstract
INTRODUCTION [18F]Fluoroestradiol ([18F]FES) PET/CT has been proposed as a tool for detecting the oestrogen receptor density in patients with metastatic breast cancer (BC) non-invasively across all disease localizations. However, its diagnostic potential in terms of the detection rate (DR) of metastases is unclear. In this study, we pitted this method against [18F]FDG PET/CT and tried to identify predictors of the diagnostic superiority of the [18F] FES-based method. MATERIALS AND METHODS From a multicentre database, we enrolled all patients with metastatic BC who had undergone both [18F]FES PET/CT and [18F]FDG PET/CT. Two readers assessed both images independently and used a patient-based (PBA) and lesion-based analysis (LBA) to calculate the DR. Pathology-related and clinical factors were tested as predictors of [18F]FES PET/CT superiority using a multivariate model. RESULTS 92 patients, bearing a total of 2678 metastases, were enrolled. On PBA, the DR of [18F]FDG and [18F]FES PET/CT was 97% and 86%, respectively (p = 0.018). On LBA, the [18F]FES method proved more sensitive than [18F]FDG PET/CT in lymph nodes, bone, lung and soft tissue (p < 0.01). This greater sensitivity was associated with lobular histology, both on PBA (Odds Ratio (OR) 3.4, 95%CI 1.0-12.3) and on LBA (OR 4.4, 95%CI 1.2-16.1 for lymph node metastases and OR 3.29, 95%CI 1.1-10.2 for bone localizations). CONCLUSIONS The overall DR of [18F]FES PET/CT appears to be lower than that of [18F]FDG PET/CT on PBA. However, the [18F]FES method, if positive, can identify more lesions than [18F]FDG at most sites. The higher sensitivity of [18F]FES PET/CT was associated with lobular histology.
Collapse
Affiliation(s)
- Gianluca Bottoni
- Department of Nuclear Medicine, E.O. "Ospedali Galliera", Mura delle Cappuccine 14, 16128, Italy
| | - Francesco Fiz
- Department of Nuclear Medicine, E.O. "Ospedali Galliera", Mura delle Cappuccine 14, 16128, Italy.
| | - Matteo Puntoni
- Clinical and Epidemiological Research Unit, University Hospital of Parma, Parma, Italy
| | - Federica Matteucci
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo studio dei tumori (IRST)- Dino Amadori, Meldola, Italy
| | - Manuela Monti
- Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo studio dei tumori (IRST)- Dino Amadori_, Meldola, Italy
| | - Andrea DeCensi
- Department of Medicine and Oncology, E.O. "Ospedali Galliera", Genoa, Italy
| | - Oriana Nanni
- Biostatistics and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo studio e la cura dei tumori, IRST, Meldola, Italy
| | - Etienne Brain
- Department of Clinical Research & Medical Oncology, Institut Curie (Hôpital René Huguenin), St Cloud, France
| | - Jean Louis Alberini
- Nuclear Medicine Department Centre Georges-Francois Leclerc, 1 rue du Pr Marion, 21079, Dijon Cedex, France
| | - Bassam Dib
- Nuclear Medicine Unit, AOU Maggiore della Carità, Novara, Italy
| | | | - Pierpaolo Trimboli
- Clinic of Endocrinology and Diabetology, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
- Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland
| | - Giorgio Treglia
- Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland
- Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500, Bellinzona, Switzerland
- Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, 1015, Lausanne, Switzerland
| | - Nadia Harbeck
- Breast Centre, Department of Obstetrics and Gynaecology, LMU University Hospital, Munich, Germany
| | - Simona Sola
- Pathology Unit, E.O. "Ospedali Galliera", Genoa, Italy
| | - Alessandra Gennari
- Department of Translational Oncology, University of Eastern Piedmont, Novara, Italy
| | - Arnoldo Piccardo
- Department of Nuclear Medicine, E.O. "Ospedali Galliera", Mura delle Cappuccine 14, 16128, Italy
| |
Collapse
|
5
|
Bugani V, Battistelli L, Sansovini M, Monti M, Paganelli G, Gich I, Flotats A, Erba PA, Blay JY, la Fougère C, Van Poppel H, Charalambous A, Herrmann K, Giordano A, Györke T, Deroose C, Matteucci F, Carrió I. Radioligand therapies in cancer: mapping the educational landscape in Europe. Eur J Nucl Med Mol Imaging 2023; 50:2692-2698. [PMID: 37058168 PMCID: PMC10102677 DOI: 10.1007/s00259-023-06217-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Accepted: 03/29/2023] [Indexed: 04/15/2023]
Abstract
AIM We performed a systematic survey to assess the existing gaps in Europe in multidisciplinary education for integration of radioligand therapy (RLT) into cancer care and to obtain detailed information on the current limitations and key contents relevant. METHODS A high-quality questionnaire, with emphasis on survey scales, formulation, and validity of the different items, was designed. An expert validation process was undertaken. The survey was circulated among medical specialties involved in cancer treatment, universities, and nursing organizations. Questionnaires (156) were distributed, and 95 responses received. RESULTS Sevety-eight percent of medical societies indicated that training in RLT was very important and 12% important. Eighty-eight percent indicated that their specialty training program included RLT. Twenty-six percent were satisfied with the existing structure of training in RLTs. Ninety-four percent indicated that the existing training is based on theory and hands-on experience. Main identified limitations were lack of centers ready to train and of personnel available for teaching. Sixty-five percent indicated that national programs could be expanded. Fifty percent of consulted universities indicated partial or scarce presence of RLT contents in their teaching programs. In 26% of the cases, the students do not have the chance to visit a RLT facility. A large majority of the universities are interested in further expansion of RLT contents in their curriculums. Nursing organizations almost never (44.4%) or occasionally (33.3%) include RLT contents in the education of nurses and technologists. Hands-on experience is almost never (38%) and sometimes (38%) offered. However, 67% of centers indicated high interest in expanding RLT contents. CONCLUSION Centers involved recognize the importance of the training and indicate a need for inclusion of additional clinical content, imaging analysis, and interpretation as well as extended hands-on training. A concerted effort to adapt current programs and a shift towards multidisciplinary training programs is necessary for proper education in RLT in Europe.
Collapse
Affiliation(s)
- Valentina Bugani
- Research, Technology Transfer and Training Office, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, Meldola, FC, 47014, Italy.
| | - Luca Battistelli
- Research, Technology Transfer and Training Office, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, Meldola, FC, 47014, Italy
| | - Maddalena Sansovini
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), "Dino Amadori", Meldola, Italy
| | - Manuela Monti
- Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Giovanni Paganelli
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), "Dino Amadori", Meldola, Italy
| | - Ignasi Gich
- Department of Pharmacology, Therapeutic and Toxicology, Autonomous University of Barcelona (UAB), Barcelona, Spain
- Clinical Epidemiology and Public Health Service, Fundació Institut de Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Albert Flotats
- Department of Nuclear Medicine, Autonomous University of Barcelona (UAB), Barcelona, Spain
- Nuclear Medicine Services, Fundació Institut de Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Paola Anna Erba
- Department of Translational Research and New Technology in Medicine and Surgery, Regional Center of Nuclear Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | - Jean-Yves Blay
- Department of Cancer Medicine, "Léon Bérard" Cancer Center, Lyon, France
- Department of Medica Oncology, University "Claude Bernard", Lyon 1, Lyon, France
| | - Christian la Fougère
- Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital of Tuebingen, Tuebingen, Germany
| | - Hendrik Van Poppel
- Department of Urology, KU University Hospitals of Leuven, Louvain, Belgium
| | - Andreas Charalambous
- Department of Nursing, Cyprus University of Technology, Limassol, Cyprus
- Department of Nursing Science, University of Turku, Turku, Finland
| | - Ken Herrmann
- Department of Nuclear Medicine, University Hospital of Essen, Essen, Germany
| | - Alessandro Giordano
- Unit of Nuclear Medicine, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
| | - Tamás Györke
- Department of Nuclear Medicine, Medical Imaging Center, "I. Semmelweis" University, Budapest, Hungary
| | - Christophe Deroose
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU University Hospitals of Leuven, Louvain, Belgium
| | - Federica Matteucci
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), "Dino Amadori", Meldola, Italy
| | - Ignasi Carrió
- Department of Nuclear Medicine, Autonomous University of Barcelona (UAB), Barcelona, Spain
- Nuclear Medicine Services, Fundació Institut de Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| |
Collapse
|
6
|
Bianchi A, De Rimini ML, Sciuto R, Annovazzi A, Di Traglia S, Bauckneht M, Lanfranchi F, Morbelli S, Nappi AG, Ferrari C, Rubini G, Panareo S, Urso L, Bartolomei M, D'Arienzo D, Valente T, Rossetti V, Caroli P, Matteucci F, Aricò D, Bombaci M, Caponnetto D, Bertagna F, Albano D, Dondi F, Gusella S, Spimpolo A, Carriere C, Balma M, Buschiazzo A, Gallicchio R, Storto G, Ruffini L, Scarlattei M, Baldari G, Cervino AR, Cuppari L, Burei M, Trifirò G, Brugola E, Zanini CA, Alessi A, Fuoco V, Seregni E, Deandreis D, Liberini V, Moreci AM, Ialuna S, Pulizzi S, Evangelista L. Can Baseline [18F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study. Cancer Biother Radiopharm 2023; 38:256-267. [PMID: 37098169 DOI: 10.1089/cbr.2022.0092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023] Open
Abstract
Aim: To assess the role of baseline 18F-fluorodeoxyglucose ([18F]FDG)-positron emission tomography/computed tomography (PET/CT) in predicting response to immunotherapy after 6 months and overall survival (OS) in patients with lung cancer (LC) or malignant melanoma (MM). Methods: Data from a multicenter, retrospective study conducted between March and November 2021 were analyzed. Patients >18 years old with a confirmed diagnosis of LC or MM, who underwent a baseline [18F]FDG-PET/CT within 1-2 months before starting immunotherapy and had a follow-up of at least 12 months were included. PET scans were examined visually and semiquantitatively by physicians at peripheral centers. The metabolic tumor burden (number of lesions with [18F]FDG-uptake) and other parameters were recorded. Clinical response was assessed at 3 and 6 months after starting immunotherapy, and OS was calculated as the time elapsing between the PET scan and death or latest follow-up. Results: The study concerned 177 patients with LC and 101 with MM. Baseline PET/CT was positive in primary or local recurrent lesions in 78.5% and 9.9% of cases, in local/distant lymph nodes in 71.8% and 36.6%, in distant metastases in 58.8% and 84%, respectively, in LC and in MM patients. Among patients with LC, [18F]FDG-uptake in primary/recurrent lung lesions was more often associated with no clinical response to immunotherapy after 6 months than in cases without any tracer uptake. After a mean 21 months, 46.5% of patients with LC and 37.1% with MM had died. A significant correlation emerged between the site/number of [18F]FDG foci and death among patients with LC, but not among those with MM. Conclusions: In patients with LC who are candidates for immunotherapy, baseline [18F]FDG-PET/CT can help to predict response to this therapy after 6 months, and to identify those with a poor prognosis based on their metabolic parameters. For patients with MM, there was only a weak correlation between baseline PET/CT parameters, response to therapy, and survival.
Collapse
Affiliation(s)
- Andrea Bianchi
- Nuclear Medicine Unit, SC Medicina Nucleare, ASO S.Croce e Carle Cuneo, Cuneo, Italy
| | - Maria Luisa De Rimini
- Nuclear Medicine Unit, Department of Health Service, AORN Ospedali dei Colli, Naples, Italy
| | - Rosa Sciuto
- Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - Alessio Annovazzi
- Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - Silvia Di Traglia
- Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - Matteo Bauckneht
- Department of Health Sciences (DISSAL), University of Genova, Genova, Italy
- Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - Francesco Lanfranchi
- Department of Health Sciences (DISSAL), University of Genova, Genova, Italy
- Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - Silvia Morbelli
- Department of Health Sciences (DISSAL), University of Genova, Genova, Italy
- Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - Anna Giulia Nappi
- Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro," Bari, Italy
| | - Cristina Ferrari
- Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro," Bari, Italy
| | - Giuseppe Rubini
- Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro," Bari, Italy
| | - Stefano Panareo
- Nuclear Medicine Unit, Oncology and Haematology Department, University Hospital of Modena, Modena, Italy
| | - Luca Urso
- Nuclear Medicine Unit, Oncology and Specialistic Department, University Hospital of Ferrara, Ferrara, Italy
| | - Mirco Bartolomei
- Nuclear Medicine Unit, Oncology and Specialistic Department, University Hospital of Ferrara, Ferrara, Italy
| | - Davide D'Arienzo
- Nuclear Medicine Unit, Department of Health Service, AORN Ospedali dei Colli, Naples, Italy
| | - Tullio Valente
- U.O.C. Radiologia, Department of Servizi, AORN Ospedali dei Colli, Napoli, Italy
| | - Virginia Rossetti
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
| | - Paola Caroli
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
| | - Federica Matteucci
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
| | - Demetrio Aricò
- Servizio di Medicina Nucleare, Humanitas Istituto Clinico Catanese, Misterbianco, Italy
| | - Michelangelo Bombaci
- Servizio di Medicina Nucleare, Humanitas Istituto Clinico Catanese, Misterbianco, Italy
| | - Domenica Caponnetto
- Servizio di Medicina Nucleare, Humanitas Istituto Clinico Catanese, Misterbianco, Italy
| | - Francesco Bertagna
- Nuclear Medicine Unit, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy
| | - Domenico Albano
- Nuclear Medicine Unit, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy
| | - Francesco Dondi
- Nuclear Medicine Unit, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy
| | - Sara Gusella
- Nuclear Medicine Department, Central Hospital Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy
| | - Alessandro Spimpolo
- Nuclear Medicine Department, Central Hospital Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy
| | - Cinzia Carriere
- Dermatology Department, Central Hospital Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy
| | - Michele Balma
- Nuclear Medicine Unit, SC Medicina Nucleare, ASO S.Croce e Carle Cuneo, Cuneo, Italy
| | - Ambra Buschiazzo
- Nuclear Medicine Unit, SC Medicina Nucleare, ASO S.Croce e Carle Cuneo, Cuneo, Italy
| | - Rosj Gallicchio
- Nuclear Medicine Unit, IRCCS CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
| | - Giovanni Storto
- Nuclear Medicine Unit, IRCCS CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
| | - Livia Ruffini
- Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy
| | - Maura Scarlattei
- Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy
| | - Giorgio Baldari
- Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy
| | - Anna Rita Cervino
- Nuclear Medicine Unit, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy
| | - Lea Cuppari
- Nuclear Medicine Unit, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy
| | - Marta Burei
- Nuclear Medicine Unit, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy
| | - Giuseppe Trifirò
- Servizio di Medicina Nucleare ICS MAUGERI SPA SB-IRCCS, Pavia, Italy
| | | | - Carolina Arianna Zanini
- Department of Nuclear Medicine, Università Degli Studi di Milano, Milano Statale, Milan, Italy
| | - Alessandra Alessi
- Nuclear Medicine Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Valentina Fuoco
- Nuclear Medicine Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Ettore Seregni
- Nuclear Medicine Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Désirée Deandreis
- Nuclear Medicine Division, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Virginia Liberini
- Nuclear Medicine Unit, SC Medicina Nucleare, ASO S.Croce e Carle Cuneo, Cuneo, Italy
- Nuclear Medicine Division, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Antonino Maria Moreci
- Nuclear Medicine Unit, Az. Ospedaliera Ospedali Riuniti Villa Sofia-Cervello di Palermo, Palermo, Italy
| | - Salvatore Ialuna
- Nuclear Medicine Unit, Az. Ospedaliera Ospedali Riuniti Villa Sofia-Cervello di Palermo, Palermo, Italy
| | - Sabina Pulizzi
- Nuclear Medicine Unit, Az. Ospedaliera Ospedali Riuniti Villa Sofia-Cervello di Palermo, Palermo, Italy
| | - Laura Evangelista
- Nuclear Medicine Unit, Department of Medicine DIMED, University of Padua, Padua, Italy
| |
Collapse
|
7
|
Altavilla A, Caroli P, Giunta EF, Scarpi E, Rossetti V, Casadei C, Lolli C, Schepisi G, Bleve S, Cursano MC, Gasperoni L, Matteucci F, De Giorgi U. Impact of 68Ga-PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide. J Clin Oncol 2023. [DOI: 10.1200/jco.2023.41.6_suppl.48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2023] Open
Abstract
48 Background: 68Ga prostate specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA PET/CT) is a highly sensitive diagnostic tool to detect prostate metastatic sites even at low levels of Prostate Specific Antigen (PSA). We evaluated the impact of 68Ga-PSMA PET/CT in patients treated with enzalutamide as first-line therapy for mCRPC. Methods: In an observational prospective study, 67 consecutive mCRPC patients were treated with enzalutamide 160 mg once daily in first-line for mCRPC. 68Ga-PSMA PET/CT was performed at baseline, after 3 months, during follow-up and at PSA/clinical progression. Patients were evaluated on a monthly basis for serological PSA response and safety. We measured at baseline the sum of metabolic total volume (SMTV), mean standardized uptake volume (SSUVmean), maximum standardized uptake volume (SSUVmax) and total lesion activity (STLA), which is the product of SMTV and SSUVmean, for a maximum of 20 lesions. These parameters together with baseline PSA level, Eastern Cooperative Oncology Group performance status (ECOG PS), Gleason Score (GS) and age were analyzed by univariate and multivariate Cox regression models as potential predictors of progression-free survival (PFS) and overall survival (OS). Results: At the moment of the present analysis, 58 mCRPC patients were considered fully evaluable. The median age was 75 years (range, 47-91), ECOG PS was 0 in 47 cases (81%), 1-2 in 11 (19%), GS was <8 in 22 (38%), 8-10 in 36 (62%), the median baseline PSA was 2.66 µg/L (range 0.09-197). We observed a median SMTV of 5.73 cm3, median SSUVmax of 44.85, median SSUVmean of 25.80 and median STLA of 59.66. At the median follow-up of 52 months, median PFS was 28.9 months (95% CI 16.3-43.6), median OS was not reached (95% CI 36.8-not reached). In univariate analysis, SSUVmax and STLA were significant for PFS (p=0.015 and p=0.001, respectively) and OS (p=0.026 and p=0.019, respectively), while SSUVmean was significant only for OS (p=0.028). On multivariate analysis, STLA only remained significant for PFS (p<0.001) and OS (p=0.026). Conclusions: The assessment of mCRPC by 68Ga-PSMA PET/CT before starting enzalutamide was associated with longer median PFS and OS compared to prior studies using standard imaging only. STLA, expression of both volume and intensity of 68Ga-PSMA uptake, appeared the strongest parameter able to predict PFS and OS.
Collapse
Affiliation(s)
- Amelia Altavilla
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Paola Caroli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | | | - Emanuela Scarpi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Virginia Rossetti
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Chiara Casadei
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Cristian Lolli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Giuseppe Schepisi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Sara Bleve
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | | | - Lorenzo Gasperoni
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Federica Matteucci
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Ugo De Giorgi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| |
Collapse
|
8
|
Evangelista L, Bianchi A, Annovazzi A, Sciuto R, Di Traglia S, Bauckneht M, Lanfranchi F, Morbelli S, Nappi AG, Ferrari C, Rubini G, Panareo S, Urso L, Bartolomei M, D’Arienzo D, Valente T, Rossetti V, Caroli P, Matteucci F, Aricò D, Bombaci M, Caponnetto D, Bertagna F, Albano D, Dondi F, Gusella S, Spimpolo A, Carriere C, Balma M, Buschiazzo A, Gallicchio R, Storto G, Ruffini L, Cervati V, Ledda RE, Cervino AR, Cuppari L, Burei M, Trifirò G, Brugola E, Zanini CA, Alessi A, Fuoco V, Seregni E, Deandreis D, Liberini V, Moreci AM, Ialuna S, Pulizzi S, De Rimini ML. ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors. Cancers (Basel) 2023; 15:cancers15030878. [PMID: 36765835 PMCID: PMC9913289 DOI: 10.3390/cancers15030878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 01/24/2023] [Accepted: 01/27/2023] [Indexed: 02/04/2023] Open
Abstract
AIM To examine the role of [18F]FDG PET/CT for assessing response to immunotherapy in patients with some solid tumors. METHODS Data recorded in a multicenter (n = 17), retrospective database between March and November 2021 were analyzed. The sample included patients with a confirmed diagnosis of a solid tumor who underwent serial [18F]FDG PET/CT (before and after one or more cycles of immunotherapy), who were >18 years of age, and had a follow-up of at least 12 months after their first PET/CT scan. Patients enrolled in clinical trials or without a confirmed diagnosis of cancer were excluded. The authors classified cases as having a complete or partial metabolic response to immunotherapy, or stable or progressive metabolic disease, based on a visual and semiquantitative analysis according to the EORTC criteria. Clinical response to immunotherapy was assessed at much the same time points as the serial PET scans, and both the obtained responses were compared. RESULTS The study concerned 311 patients (median age: 67; range: 31-89 years) in all. The most common neoplasm was lung cancer (56.9%), followed by malignant melanoma (32.5%). Nivolumab was administered in 46.3%, and pembrolizumab in 40.5% of patients. Baseline PET and a first PET scan performed at a median 3 months after starting immunotherapy were available for all 311 patients, while subsequent PET scans were obtained after a median 6, 12, 16, and 21 months for 199 (64%), 102 (33%), 46 (15%), and 23 (7%) patients, respectively. Clinical response to therapy was recorded at around the same time points after starting immunotherapy for 252 (81%), 173 (56%), 85 (27%), 40 (13%), and 22 (7%) patients, respectively. After a median 18 (1-137) months, 113 (36.3%) patients had died. On Kaplan-Meier analysis, metabolic responders on the first two serial PET scans showed a better prognosis than non-responders, while clinical response became prognostically informative from the second assessment after starting immunotherapy onwards. CONCLUSIONS [18F]FDG PET/CT could have a role in the assessment of response to immunotherapy in patients with some solid tumors. It can provide prognostic information and thus contribute to a patient's appropriate treatment. Prospective randomized controlled trials are mandatory.
Collapse
Affiliation(s)
- Laura Evangelista
- Nuclear Medicine Unit, Department of Medicine DIMED, University of Padua, 35129 Padua, Italy
- Correspondence:
| | - Andrea Bianchi
- Nuclear Medicine Unit, ASO S.Croce e Carle Cuneo, 12100 Cuneo, Italy
| | - Alessio Annovazzi
- Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy
| | - Rosa Sciuto
- Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy
| | - Silvia Di Traglia
- Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy
| | - Matteo Bauckneht
- Department of Health Sciences (DISSAL), University of Genova, 16126 Genova, Italy
- Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
| | - Francesco Lanfranchi
- Department of Health Sciences (DISSAL), University of Genova, 16126 Genova, Italy
- Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
| | - Silvia Morbelli
- Department of Health Sciences (DISSAL), University of Genova, 16126 Genova, Italy
- Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
| | - Anna Giulia Nappi
- Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari “Aldo Moro”, 70121 Bari, Italy
| | - Cristina Ferrari
- Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari “Aldo Moro”, 70121 Bari, Italy
| | - Giuseppe Rubini
- Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari “Aldo Moro”, 70121 Bari, Italy
| | - Stefano Panareo
- Nuclear Medicine Unit, Azienda Ospedaliero Universitaria di Modena, 41124 Modena, Italy
| | - Luca Urso
- Nuclear Medicine Unit, University of Ferrara, 44121 Ferrara, Italy
| | - Mirco Bartolomei
- Nuclear Medicine Unit, University of Ferrara, 44121 Ferrara, Italy
| | - Davide D’Arienzo
- Nuclear Medicine Unit, Dept Servizi Sanitari, AORN Ospedali dei Colli, 80131 Naples, Italy
| | - Tullio Valente
- Radiology Department, AORN Ospedali dei Colli, 80131 Naples, Italy
| | - Virginia Rossetti
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), 47014 Meldola, Italy
| | - Paola Caroli
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), 47014 Meldola, Italy
| | - Federica Matteucci
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), 47014 Meldola, Italy
| | - Demetrio Aricò
- Nuclear Medicine Unit, Humanitas Istituto Clinico Catanese, 95045 Misterbianco, Italy
| | - Michelangelo Bombaci
- Nuclear Medicine Unit, Humanitas Istituto Clinico Catanese, 95045 Misterbianco, Italy
| | - Domenica Caponnetto
- Nuclear Medicine Unit, Humanitas Istituto Clinico Catanese, 95045 Misterbianco, Italy
| | | | - Domenico Albano
- Nuclear Medicine Unit, University of Brescia, 25123 Brescia, Italy
| | - Francesco Dondi
- Nuclear Medicine Unit, University of Brescia, 25123 Brescia, Italy
| | - Sara Gusella
- Nuclear Medicine Department, Central Hospital Bolzano (SABES-ASDAA), 39100 Bolzano-Bozen, Italy
| | - Alessandro Spimpolo
- Nuclear Medicine Department, Central Hospital Bolzano (SABES-ASDAA), 39100 Bolzano-Bozen, Italy
| | - Cinzia Carriere
- Dermatology Department, Central Hospital Bolzano (SABES-ASDAA), 39100 Bolzano-Bozen, Italy
| | - Michele Balma
- Nuclear Medicine Unit, ASO S.Croce e Carle Cuneo, 12100 Cuneo, Italy
| | - Ambra Buschiazzo
- Nuclear Medicine Unit, ASO S.Croce e Carle Cuneo, 12100 Cuneo, Italy
| | - Rosj Gallicchio
- Nuclear Medicine Unit, IRCCS CROB Referral Cancer Center of Basilicata, 85028 Rionero in Vulture, Italy
| | - Giovanni Storto
- Nuclear Medicine Unit, IRCCS CROB Referral Cancer Center of Basilicata, 85028 Rionero in Vulture, Italy
| | - Livia Ruffini
- Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, 43126 Parma, Italy
| | - Veronica Cervati
- Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, 43126 Parma, Italy
| | - Roberta Eufrasia Ledda
- Department of Medicine and Surgery, Unit of Radiological Sciences, University of Parma, 43126 Parma, Italy
| | - Anna Rita Cervino
- Nuclear Medicine Unit, Veneto Institute Of Oncology IOV—IRCSS, 35128 Padua, Italy
| | - Lea Cuppari
- Nuclear Medicine Unit, Veneto Institute Of Oncology IOV—IRCSS, 35128 Padua, Italy
| | - Marta Burei
- Nuclear Medicine Unit, Veneto Institute Of Oncology IOV—IRCSS, 35128 Padua, Italy
| | - Giuseppe Trifirò
- Nuclear Medicine Unit, ICS MAUGERI SPA SB—IRCCS, 35128 Padua, Italy
| | | | | | - Alessandra Alessi
- Nuclear Medicine Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
| | - Valentina Fuoco
- Nuclear Medicine Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
| | - Ettore Seregni
- Nuclear Medicine Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
| | - Désirée Deandreis
- Nuclear Medicine Division, Department of Medical Sciences, University of Turin, 10124 Turin, Italy
| | - Virginia Liberini
- Nuclear Medicine Unit, ASO S.Croce e Carle Cuneo, 12100 Cuneo, Italy
- Nuclear Medicine Division, Department of Medical Sciences, University of Turin, 10124 Turin, Italy
| | - Antonino Maria Moreci
- Nuclear Medicine Unit, Az. Ospedaliera Ospedali Riuniti Villa Sofia-Cervello di Palermo, 90100 Palermo, Italy
| | - Salvatore Ialuna
- Nuclear Medicine Unit, Az. Ospedaliera Ospedali Riuniti Villa Sofia-Cervello di Palermo, 90100 Palermo, Italy
| | - Sabina Pulizzi
- Nuclear Medicine Unit, Az. Ospedaliera Ospedali Riuniti Villa Sofia-Cervello di Palermo, 90100 Palermo, Italy
| | - Maria Luisa De Rimini
- Nuclear Medicine Unit, Dept Servizi Sanitari, AORN Ospedali dei Colli, 80131 Naples, Italy
| |
Collapse
|
9
|
Lederer-Woods C, Aberle O, Andrzejewski J, Audouin L, Bécares V, Bacak M, Balibrea J, Barbagallo M, Barros S, Battino U, Bečvář F, Beinrucker C, Berthoumieux E, Billowes J, Bosnar D, Brugger M, Caamaño M, Calviño F, Calviani M, Cano-Ott D, Cardella R, Casanovas A, Castelluccio DM, Cerutti F, Chen YH, Chiaveri E, Colonna N, Cortés G, Cortés-Giraldo MA, Cosentino L, Damone LA, Diakaki M, Domingo-Pardo C, Dressler R, Dupont E, Durán I, Fernández-Domínguez B, Ferrari A, Ferreira P, Finocchiaro P, Furman V, Göbel K, García AR, Gawlik-Ramięga A, Glodariu T, Gonçalves IF, González-Romero E, Goverdovski A, Griesmayer E, Guerrero C, Gunsing F, Harada H, Heftrich T, Heinitz S, Heyse J, Jenkins DG, Jericha E, Käppeler F, Kadi Y, Katabuchi T, Kavrigin P, Ketlerov V, Khryachkov V, Kimura A, Kivel N, Kokkoris M, Krtička M, Leal-Cidoncha E, Leeb H, Lerendegui-Marco J, Meo SL, Lonsdale SJ, Losito R, Macina D, Marganiec J, Martínez T, Massimi C, Mastinu P, Mastromarco M, Matteucci F, Maugeri EA, Mendoza E, Mengoni A, Milazzo PM, Mingrone F, Mirea M, Montesano S, Musumarra A, Nolte R, Oprea A, Patronis N, Pavlik A, Perkowski J, Porras I, Praena J, Quesada JM, Rajeev K, Rauscher T, Reifarth R, Riego-Perez A, Rout PC, Rubbia C, Ryan JA, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schmidt S, Schumann D, Sedyshev P, Smith AG, Stamatopoulos A, Tagliente G, Tain JL, Tarifeño-Saldivia A, Tassan-Got L, Tsinganis A, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Wallner A, Warren S, Weigand M, Weiss C, Wolf C, Woods PJ, Wright T, Žugec P. 74 Ge( n , γ ) cross section below 70 keV measured at n_TOF CERN. Eur Phys J A Hadron Nucl 2022; 58:239. [PMID: 36514540 PMCID: PMC9734248 DOI: 10.1140/epja/s10050-022-00878-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Accepted: 10/31/2022] [Indexed: 06/17/2023]
Abstract
Neutron capture reaction cross sections on 74 Ge are of importance to determine 74 Ge production during the astrophysical slow neutron capture process. We present new resonance data on 74 Ge( n , γ ) reactions below 70 keV neutron energy. We calculate Maxwellian averaged cross sections, combining our data below 70 keV with evaluated cross sections at higher neutron energies. Our stellar cross sections are in agreement with a previous activation measurement performed at Forschungszentrum Karlsruhe by Marganiec et al., once their data has been re-normalised to account for an update in the reference cross section used in that experiment.
Collapse
Affiliation(s)
- C. Lederer-Woods
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, UK
| | - O. Aberle
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - L. Audouin
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, 91406 Orsay Cedex, France
| | - V. Bécares
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - M. Bacak
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
| | - J. Balibrea
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - M. Barbagallo
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - S. Barros
- Instituto Superior Técnico, Lisbon, Portugal
| | | | - F. Bečvář
- Charles University, Prague, Czech Republic
| | | | - E. Berthoumieux
- CEA Irfu, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | | | - D. Bosnar
- Department of Physics, Faculty of Science, University of Zagreb, Zagreb, Croatia
| | - M. Brugger
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - M. Caamaño
- University of Santiago de Compostela, Santiago, Spain
| | - F. Calviño
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | - M. Calviani
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - D. Cano-Ott
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - R. Cardella
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A. Casanovas
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | - D. M. Castelluccio
- Agenzia nazionale per le nuove tecnologie (ENEA), Bologna, Italy
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - F. Cerutti
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - Y. H. Chen
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, 91406 Orsay Cedex, France
| | - E. Chiaveri
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - N. Colonna
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - G. Cortés
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | | | - L. Cosentino
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - L. A. Damone
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
- Dipartimento Interateneo di Fisica, Università degli Studi di Bari, Bari, Italy
| | - M. Diakaki
- CEA Irfu, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - C. Domingo-Pardo
- Instituto de Física Corpuscular, CSIC-Universidad de Valencia, Valencia, Spain
| | - R. Dressler
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - E. Dupont
- CEA Irfu, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - I. Durán
- University of Santiago de Compostela, Santiago, Spain
| | | | - A. Ferrari
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - P. Ferreira
- Instituto Superior Técnico, Lisbon, Portugal
| | | | - V. Furman
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - K. Göbel
- Goethe University Frankfurt, Frankfurt, Germany
| | - A. R. García
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | | | - T. Glodariu
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Magurele, Romania
| | | | - E. González-Romero
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A. Goverdovski
- Institute of Physics and Power Engineering (IPPE), Obninsk, Russia
| | - E. Griesmayer
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
| | | | - F. Gunsing
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- CEA Irfu, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - H. Harada
- Japan Atomic Energy Agency (JAEA), Tokai-Mura, Japan
| | - T. Heftrich
- Goethe University Frankfurt, Frankfurt, Germany
| | - S. Heinitz
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - J. Heyse
- European Commission, Joint Research Centre (JRC), Geel, Belgium
| | | | - E. Jericha
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
| | - F. Käppeler
- Karlsruhe Institute of Technology, Campus North, IKP, 76021 Karlsruhe, Germany
| | - Y. Kadi
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - P. Kavrigin
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
| | - V. Ketlerov
- Institute of Physics and Power Engineering (IPPE), Obninsk, Russia
| | - V. Khryachkov
- Institute of Physics and Power Engineering (IPPE), Obninsk, Russia
| | - A. Kimura
- Japan Atomic Energy Agency (JAEA), Tokai-Mura, Japan
| | - N. Kivel
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - M. Kokkoris
- National Technical University of Athens, Athens, Greece
| | - M. Krtička
- Charles University, Prague, Czech Republic
| | | | - H. Leeb
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
| | | | - S. Lo Meo
- Agenzia nazionale per le nuove tecnologie (ENEA), Bologna, Italy
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - S. J. Lonsdale
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, UK
| | - R. Losito
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - D. Macina
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | | | - T. Martínez
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - C. Massimi
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Bologna, Italy
| | - P. Mastinu
- Istituto Nazionale di Fisica Nucleare, Sezione di Legnaro, Italy
| | - M. Mastromarco
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - F. Matteucci
- Istituto Nazionale di Fisica Nucleare, Sezione di Trieste, Italy
- Dipartimento di Astronomia, Università di Trieste, Trieste, Italy
| | | | - E. Mendoza
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A. Mengoni
- Agenzia nazionale per le nuove tecnologie (ENEA), Bologna, Italy
| | - P. M. Milazzo
- Istituto Nazionale di Fisica Nucleare, Sezione di Trieste, Italy
| | - F. Mingrone
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - M. Mirea
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Magurele, Romania
| | - S. Montesano
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A. Musumarra
- INFN Laboratori Nazionali del Sud, Catania, Italy
- Dipartimento di Fisica e Astronomia, Università di Catania, Catania, Italy
| | - R. Nolte
- Physikalisch-Technische Bundesanstalt (PTB), Bundesallee 100, 38116 Braunschweig, Germany
| | - A. Oprea
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Magurele, Romania
| | | | - A. Pavlik
- Faculty of Physics, University of Vienna, Vienna, Austria
| | | | - I. Porras
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- University of Granada, Granada, Spain
| | - J. Praena
- University of Granada, Granada, Spain
| | | | - K. Rajeev
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - T. Rauscher
- Centre for Astrophysics Research, University of Hertfordshire, Hatfield, UK
- Department of Physics, University of Basel, Basel, Switzerland
| | - R. Reifarth
- Goethe University Frankfurt, Frankfurt, Germany
| | | | - P. C. Rout
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - C. Rubbia
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J. A. Ryan
- University of Manchester, Manchester, UK
| | - M. Sabaté-Gilarte
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Universidad de Sevilla, Seville, Spain
| | - A. Saxena
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | | | - S. Schmidt
- Goethe University Frankfurt, Frankfurt, Germany
| | - D. Schumann
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - P. Sedyshev
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | | | | | - G. Tagliente
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - J. L. Tain
- Instituto de Física Corpuscular, CSIC-Universidad de Valencia, Valencia, Spain
| | | | - L. Tassan-Got
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, 91406 Orsay Cedex, France
| | - A. Tsinganis
- National Technical University of Athens, Athens, Greece
| | - S. Valenta
- Charles University, Prague, Czech Republic
| | - G. Vannini
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Bologna, Italy
| | - V. Variale
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - P. Vaz
- Instituto Superior Técnico, Lisbon, Portugal
| | - A. Ventura
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - V. Vlachoudis
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - R. Vlastou
- National Technical University of Athens, Athens, Greece
| | - A. Wallner
- Australian National University, Canberra, Australia
| | - S. Warren
- University of Manchester, Manchester, UK
| | - M. Weigand
- Goethe University Frankfurt, Frankfurt, Germany
| | - C. Weiss
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- TU Wien, Atominstitut, Stadionallee 2, 1020 Wien, Austria
| | - C. Wolf
- Goethe University Frankfurt, Frankfurt, Germany
| | - P. J. Woods
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, UK
| | - T. Wright
- University of Manchester, Manchester, UK
| | - P. Žugec
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Department of Physics, Faculty of Science, University of Zagreb, Zagreb, Croatia
| | | |
Collapse
|
10
|
Gennari A, Brain E, Nanni O, Harbeck N, Cortés J, De Censi A, Piccardo A, Alberini J, Matteucci F, Sacchetti G, Ilhan H, Monti M, Wuerlestein R, Saggia C, Rossi V, D'Avanzo F, Maggiora P, Iacozzi M, Frassoldati A, Boni L. 221P Early prediction of efficacy of endocrine therapy (ET) in metastatic breast cancer (MBC): Pilot study with [18F]fluoro-estradiol-17β (18F-FES) PET/CT. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
11
|
Calistri E, Fuentes T, Morganti R, Sainato A, Manfredi B, Matteucci F, Pasqualetti F, Paiar F. PO-1383 Adjuvant versus salvage radiotherapy in patiens with prostate cancer: a monocentric experience. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03347-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
12
|
Fuentes T, Calistri E, Sainato A, Manfredi B, Matteucci F, Morganti R, Pasqualetti F, Paiar F. PO-1368 Prophylactic pelvic nodal RT vs only prostate bed irradiation in patients with prostatic cancer. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03332-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
13
|
Feliciani G, Celli M, Ferroni F, Menghi E, Azzali I, Caroli P, Matteucci F, Barone D, Paganelli G, Sarnelli A. Radiomics Analysis on [68Ga]Ga-PSMA-11 PET and MRI-ADC for the Prediction of Prostate Cancer ISUP Grades: Preliminary Results of the BIOPSTAGE Trial. Cancers (Basel) 2022; 14:cancers14081888. [PMID: 35454793 PMCID: PMC9028386 DOI: 10.3390/cancers14081888] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Revised: 04/01/2022] [Accepted: 04/06/2022] [Indexed: 02/01/2023] Open
Abstract
Simple Summary Radiomics analysis is used on magnetic resonance imaging – apparent diffusion coefficient (MRI-ADC) maps and [68Ga]Ga-PSMA-11 PET uptake maps to assess unique tumor traits not visible to the naked eye and predict histology-proven ISUP grades in a cohort of 28 patients. Our study’s main goal is to report imaging features that can distinguish patients with low ISUP grades from those with higher grades (ISUP one+) by employing logistic regression statistical models based on MRI-ADC and 68Ga-PSMA data, as well as assess the features’ stability under small contouring variations. Our findings reveal that MRI-ADC and [68Ga]Ga-PSMA-11 PET imaging features-based models are equivalent and complementary for predicting low ISUP grade patients. These models can be employed in broader studies to confirm their ISUP grade prediction ability and eventually impact clinical workflow by reducing overdiagnosis of indolent, early-stage PCa. Abstract Prostate cancer (PCa) risk categorization based on clinical/PSA testing results in a substantial number of men being overdiagnosed with indolent, early-stage PCa. Clinically non-significant PCa is characterized as the presence of ISUP grade one, where PCa is found in no more than two prostate biopsy cores.MRI-ADC and [68Ga]Ga-PSMA-11 PET have been proposed as tools to predict ISUP grade one patients and consequently reduce overdiagnosis. In this study, Radiomics analysis is applied to MRI-ADC and [68Ga]Ga-PSMA-11 PET maps to quantify tumor characteristics and predict histology-proven ISUP grades. ICC was applied with a threshold of 0.6 to assess the features’ stability with variations in contouring. Logistic regression predictive models based on imaging features were trained on 31 lesions to differentiate ISUP grade one patients from ISUP two+ patients. The best model based on [68Ga]Ga-PSMA-11 PET returned a prediction efficiency of 95% in the training phase and 100% in the test phase whereas the best model based on MRI-ADC had an efficiency of 100% in both phases. Employing both imaging modalities, prediction efficiency was 100% in the training phase and 93% in the test phase. Although our patient cohort was small, it was possible to assess that both imaging modalities add information to the prediction models and show promising results for further investigations.
Collapse
Affiliation(s)
- Giacomo Feliciani
- Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy; (E.M.); (A.S.)
- Correspondence: ; Tel.: +39-327-4730398
| | - Monica Celli
- Nuclear Medicine and Radiometabolic Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy; (M.C.); (P.C.); (F.M.); (G.P.)
| | - Fabio Ferroni
- Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy; (F.F.); (D.B.)
| | - Enrico Menghi
- Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy; (E.M.); (A.S.)
| | - Irene Azzali
- Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy;
| | - Paola Caroli
- Nuclear Medicine and Radiometabolic Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy; (M.C.); (P.C.); (F.M.); (G.P.)
| | - Federica Matteucci
- Nuclear Medicine and Radiometabolic Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy; (M.C.); (P.C.); (F.M.); (G.P.)
| | - Domenico Barone
- Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy; (F.F.); (D.B.)
| | - Giovanni Paganelli
- Nuclear Medicine and Radiometabolic Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy; (M.C.); (P.C.); (F.M.); (G.P.)
| | - Anna Sarnelli
- Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy; (E.M.); (A.S.)
| |
Collapse
|
14
|
Conteduca V, Scarpi E, Rossi A, Ferroni F, Gurioli G, Bleve S, Gianni C, Schepisi G, Brighi N, Lolli C, Cursano MC, Virga A, Casadei C, Altavilla A, Farolfi A, Ulivi P, Barone D, Matteucci F, Paganelli G, De Giorgi U. Association of changing bone metastatic (mets) patterns with dynamics of circulating tumor DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.6_suppl.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
152 Background: Accurate monitoring response of bone mets to treatment is an active need for mCRPC patients (pts). Recently, ctDNA has been showed as an early biomarker efficacy of androgen receptor signaling inhibitor (ARSI) therapy for mCRPC ( Conteduca, Br J Cancer 2020). In this study, we aimed to reveal if ctDNA analysis can permit more reliable prediction of bone mets burden and radiographic progression disease (PD). Methods: In a biomarker study (REC 2192/2013), targeted next generation sequencing was performed to assess ctDNA fraction. Radiographic evidence of bone disease was documented by conventional imaging according to PCWG3 criteria ( Scher, J Clin Oncol 2018), and was classified on the basis of mets number (≤5, 6 -19, ≥20) in oligometastatic (O), diffuse (D), and widespread (W), respectively. Associations were explored both through uni/multivariate logistic regressions. Results: Serial plasma samples and radiographic scans on ARSI treatment were prospectively collected from 73 CRPC with bone mets. Median age was 74 years [interquartile range (IQR) 69-79]. Bone mets patterns were significantly associated with median baseline ctDNA level (O = 0.16, D = 0.33, and W = 0.46, p 0.0003). Similar results were reported on treatment and at PD (p 0.0003 and p 0.0007, respectively). In 24 pts with a progressive worsening of bone mets pattern (O→D→W) compared to pts with no change in bone mets pattern on ARSI, we observed an early meaningful ctDNA rise with a % ctDNA variation from baseline to 3 month therapy of 150.6% (IQR 104.9-210.7) vs 11.1% (IQR 0-36.6), p < 0.0001. Univariate analysis showed that early ctDNA rise was significantly associated with radiographic progression free/overall survival (rPFS/OS): hazard ratio (HR) 2.06, 95% confidence interval (CI) 1.30-3.27, p 0.002, and HR 1.82, 95% CI 1.15-2.88, p 0.01, respectively]. In multivariable analyses including ctDNA variation, changing bone mets pattern, age, performance status, and presence of concomitant visceral mets, ctDNA change at 3 month ARSI resulted the only independent predictor of both rPFS/OS (HR 2.27, 95% CI 1.04-4.94, p 0.027 and HR 2.98, 95% CI 1.31-6.81, p 0.033, respectively). Visceral mets were associated with only OS (HR 3.87, 95% CI 1.76-8.51, p 0.0008). Conclusions: Early ctDNA variation may reflect changes in bone mets pattern on ARSI allowing to track pattern of bone progression and predict outcome. Further studies to validate these findings are warranted.
Collapse
Affiliation(s)
- Vincenza Conteduca
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Emanuela Scarpi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Alice Rossi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Fabio Ferroni
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Giorgia Gurioli
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Sara Bleve
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori “Dino Amadori” (IRST) IRCCS, Meldola, Italy
| | - Caterina Gianni
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Giuseppe Schepisi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Nicole Brighi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Cristian Lolli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | | | - Alessandra Virga
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Chiara Casadei
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy
| | - Amelia Altavilla
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Alberto Farolfi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
| | - Paola Ulivi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Domenico Barone
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Federica Matteucci
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Giovanni Paganelli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Ugo De Giorgi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| |
Collapse
|
15
|
Monti M, Degenhardt T, Brain E, Wuerstlein R, Argusti A, Puntoni M, Rollandi GA, Corradengo D, Boni L, Ilhan H, Nanni O, Cortes J, Piris-Gimenez A, Piccardo A, Iacozzi M, Matteucci F, Di Iorio V, Alberini JL, Schröder C, Harbeck N, Gennari A. ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study. Front Med (Lausanne) 2022; 8:817678. [PMID: 35096909 PMCID: PMC8794579 DOI: 10.3389/fmed.2021.817678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Accepted: 12/22/2021] [Indexed: 11/17/2022] Open
Abstract
Background: Academic research is important to face unmet medical needs. The Oncological community encounters many hurdles in setting up multicenter investigator-driven trials mainly due to administrative complexity. The purpose of a network organization at a multinational level is to facilitate clinical trials through standardization, coordination, and education for drug development and regulatory approval. Methods: The application of an European grant foresees the creation of a consortium which aims at facilitating multi-center academic clinical trials. Results: The ERA-NET TRANSCAN Call 2011 on “Validation of biomarkers for personalized cancer medicine” was released on December 2011. This project included Italian, Spanish, French and German centers. The approval process included Consortium constitution, project submission, Clinical Trial Submission, and activation on a national level. The different timescales for submitting study documents in each Country and the misalignment of objections by each Competent Authority CA, generated several requests for changes to the study documents which meant amendments had to be made; as requested by the 2001/20/EC Directive, the alignment of core documents is mandatory. This procedure impacted significantly on study activation timelines. Time to first patient in was 14, 10, 28, and 31 months from the date of submission in Italy, France, Spain, and Germany, respectively. Accrual was stopped on 22nd January 2021 due to an 18F FES shortage as the primary reason but also for having exceeded the project deadlines with consequent exhaustion of the funds allocated for the project. Conclusions: Pharmaceutical companies might be reluctant to fund research projects aimed at treatment individualization if the approval for a wider indication has already been achieved. Academic trials therefore become fundamental for promoting trials which are not attractive to big pharma. It was very difficult and time consuming to activate an academic clinical trial, for this reason, a study may become “old” as new drugs entered into the market. National institutions should promote the development of clinical research infrastructures and network with competence in regulatory, ethical, and legal skills to speed up academic research.
Collapse
Affiliation(s)
- Manuela Monti
- Unit of Biostatistics and Clinical Trials, Istituto di Ricovero e Cura a Carattere Scienteifico Istituto Romagnolo per lo Studio dei Tumori "DinoAmadori", Meldola, Italy
| | - Tom Degenhardt
- Breast Center, Department of Obstetrics and Gynaecology, Ludwig Maximilians University Hospital of Munich, Munich, Germany
| | - Etienne Brain
- Department of Clinical Research and Medical Oncology, Institut Curie-Hopital "René Huguenin", Saint-Cloud, France
| | - Rachel Wuerstlein
- Breast Center, Department of Obstetrics and Gynaecology, Ludwig Maximilians University Hospital of Munich, Munich, Germany
| | - Alessandra Argusti
- Clinical Trial Research Unit, Ente Ospedaliero Galliera Hospital, Genoa, Italy
| | - Matteo Puntoni
- Clinical Trial Research Unit, Ente Ospedaliero Galliera Hospital, Genoa, Italy
| | | | - Davide Corradengo
- Clinical Trial Research Unit, Ente Ospedaliero Galliera Hospital, Genoa, Italy
| | - Luca Boni
- Clinical Trials Unit, Istituto Nazionale per la Ricerca sul Cancro Istituto Scientifico Tumori, Genoa, Italy
| | - Harun Ilhan
- Die Radiologie (Centre for Radiology, Nuclear Medicine and Radiotherapy), Munich, Germany
| | - Oriana Nanni
- Unit of Biostatistics and Clinical Trials, Istituto di Ricovero e Cura a Carattere Scienteifico Istituto Romagnolo per lo Studio dei Tumori "DinoAmadori", Meldola, Italy
| | - Javier Cortes
- Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - Alejandro Piris-Gimenez
- Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - Arnoldo Piccardo
- Department of Nuclear Medicine, Ente Ospedaliero Galliera Hospitals, Genoa, Italy
| | - Massimiliano Iacozzi
- Department of Nuclear Medicine, Ente Ospedaliero Galliera Hospitals, Genoa, Italy
| | - Federica Matteucci
- Unit of Biostatistics and Clinical Trials, Istituto di Ricovero e Cura a Carattere Scienteifico Istituto Romagnolo per lo Studio dei Tumori "DinoAmadori", Meldola, Italy
| | - Valentina Di Iorio
- Unit of Biostatistics and Clinical Trials, Istituto di Ricovero e Cura a Carattere Scienteifico Istituto Romagnolo per lo Studio dei Tumori "DinoAmadori", Meldola, Italy
| | - Jean Louis Alberini
- Nuclear Medicine Department, Centre "Georges-François Leclerc", Dijon, France
| | - Carolien Schröder
- Department of Medical Oncology, Dutch Cancer Institute Nederlands Kanker Instituut - Antoni Van Leeuwenhoek, Amsterdam, Netherlands
| | - Nadia Harbeck
- Breast Center, Department of Obstetrics and Gynaecology, Ludwig Maximilians University Hospital of Munich, Munich, Germany
| | - Alessandra Gennari
- Department of Translational Oncology, University of Eastern Piedmont, Novara, Italy
| |
Collapse
|
16
|
Recine F, De Vita A, Fausti V, Pieri F, Bongiovanni A, Franchini E, Casadei R, Falasconi MC, Oboldi D, Matteucci F, Pallotti MC, Mercatali L, Riva N, Gurrieri L, Vanni S, Liverani C, Miserocchi G, Spadazzi C, Cocchi C, Ibrahim T. Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy. Front Oncol 2022; 11:740676. [PMID: 35070960 PMCID: PMC8776642 DOI: 10.3389/fonc.2021.740676] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Accepted: 12/10/2021] [Indexed: 12/12/2022] Open
Abstract
Background NTRK (neurotrophic tyrosine receptor kinase)-rearranged spindle cell neoplasms are a new group of tumors included in the new 5th edition of the World Health Organization (WHO) classification of soft Tissue and Bone Sarcomas. These tumors are characterized by NTRK gene fusions and show a wide spectrum of histologies and clinical behavior. Several targeted therapies have recently been approved for tumors harboring NTRK fusions, including STS. Case Presentation A 26-year-old male with advanced, pretreated NTRK rearranged spindle cell neoplasm and liver, lung and bone metastases was treated with larotrectinib on a continuous 28-day schedule, at a dose of 100 mg twice daily. An 18FDG-PET/CT scan performed after 7 days of treatment showed tumor shrinkage in both visceral and bone lesions. There was no drug-related toxicity. Subsequent evaluations confirmed continued tumor regression in disease sites. The patient is well and continues treatment. Conclusion The clinical and radiological response of our patient with an uncommon TPM4 (exon 7)-NTRK1 (exon 12) gene fusion tumor treated with a first-generation TRK inhibitor could contribute to a better understanding of the biology of this new STS entity and help to improve patient management.
Collapse
Affiliation(s)
- Federica Recine
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Alessandro De Vita
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Valentina Fausti
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Federica Pieri
- Pathology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy
| | - Alberto Bongiovanni
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Eugenia Franchini
- Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | | | | | - Devil Oboldi
- Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Federica Matteucci
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Maria Caterina Pallotti
- Palliative Care Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Laura Mercatali
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Nada Riva
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Lorena Gurrieri
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Silvia Vanni
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Chiara Liverani
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Giacomo Miserocchi
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Chiara Spadazzi
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Claudia Cocchi
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Toni Ibrahim
- Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| |
Collapse
|
17
|
Conteduca V, Scarpi E, Caroli P, Lolli C, Gurioli G, Brighi N, Poti G, Farolfi A, Altavilla A, Schepisi G, Matteucci F, Paganelli G, De Giorgi U. Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome. Mol Oncol 2022; 16:538-548. [PMID: 34657387 PMCID: PMC8763654 DOI: 10.1002/1878-0261.13120] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Revised: 09/01/2021] [Accepted: 10/15/2021] [Indexed: 11/07/2022] Open
Abstract
Plasma tumour DNA (ptDNA) is a potential early noninvasive biomarker of treatment outcome in metastatic castration-resistant prostate cancer (mCRPC). Herein, we investigated whether pretreatment ptDNA levels reflect metabolic tumour burden in mCRPC and better predict treatment outcome in combination with functional imaging. Targeted next-generation sequencing was performed to estimate the ptDNA fraction from 102 mCRPC patients receiving abiraterone or enzalutamide. The maximum standardized uptake value (SUVmax), total lesion activity (TLA) and metabolic tumour volume (MTV) were evaluated on 18 F-fluorocholine positron emission tomography/computed tomography. We assessed a Weibull multiple regression model to determine the combined impact of clinical, molecular and imaging characteristics on overall survival (OS) and progression-free survival (PFS), and to obtain prognostic scores. A significant association was seen between ptDNA and SUVmax, MTV and TLA. For survival analysis, patients were randomly allocated into a training (n = 68) and a validation (n = 34) set. In the training set, multivariable analyses showed that ptDNA, MTV and serum lactate dehydrogenase together with visceral metastasis were independent predictors of both OS and PFS. Prognostic scores were generated, with the identification of three groups of patients with significantly different median OS (29.2, 15.9 and 8.7 months) and PFS (13.3, 7.7 and 3.2 months) probabilities. The differences in median survival between risk groups were confirmed in the validation cohort for both OS and PFS. In our study, we showed that integrating plasma DNA analysis with functional imaging may improve prognostic risk stratification and treatment selection in mCRPC.
Collapse
Affiliation(s)
- Vincenza Conteduca
- Department of Medical OncologyIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
- Unit of Medical Oncology and Biomolecular TherapyDepartment of Medical and Surgical SciencesUniversity of Foggia, Policlinico RiunitiItaly
| | - Emanuela Scarpi
- Unit of Biostatistics and Clinical TrialsIRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
| | - Paola Caroli
- Nuclear Medicine Operative UnitIRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
| | - Cristian Lolli
- Department of Medical OncologyIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
| | - Giorgia Gurioli
- Biosciences LaboratoryIRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
| | - Nicole Brighi
- Department of Medical OncologyIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
| | - Giulia Poti
- Istituto Dermopatico dell'ImmacolataIDI‐IRCCSRomeItaly
| | - Alberto Farolfi
- Department of Medical OncologyIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
| | - Amelia Altavilla
- Department of Medical OncologyIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
| | - Giuseppe Schepisi
- Department of Medical OncologyIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
| | - Federica Matteucci
- Nuclear Medicine Operative UnitIRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
| | - Giovanni Paganelli
- Nuclear Medicine Operative UnitIRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
| | - Ugo De Giorgi
- Department of Medical OncologyIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”MeldolaItaly
| |
Collapse
|
18
|
Guglielmo P, Quartuccio N, Rossetti V, Celli M, Alongi P, Boero M, Arnone G, Baldari S, Matteucci F, Laudicella R. [ 18F] Fluorothymidine Positron Emission Tomography Imaging in Primary Brain Tumours: A Systematic Review. Curr Med Imaging 2022; 18:363-371. [PMID: 34533446 DOI: 10.2174/1573405617666210917123012] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2020] [Revised: 06/15/2021] [Accepted: 06/22/2021] [Indexed: 02/07/2023]
Abstract
PURPOSE This review aimed to summarize the available literature on the clinical application of [18F] FLT PET imaging in primary brain tumours. METHODS A comprehensive search strategy based on Pubmed/Medline, Scopus, Web of Science, Cochrane Library, Google Scholar, and the Embase databases was carried on using the following search string: ('3` Fluorothymidine'/exp OR 'FLT' OR '[81F]-FLT' OR '[18F] Fluorothymidine') AND ('pet'/exp OR 'pet' OR 'positron emission tomography') AND ('glioma'/exp OR 'glioma' OR 'brain tumour'/exp OR 'brain tumour'). The search was updated till March 2021 and only articles in English and studies investigating the clinical applications of [18F] FLT PET and PET/CT in primary brain tumours were considered eligible for inclusion. RESULTS The literature search ultimately yielded 52 studies included in the systematic review, with main results as follows: a) the uptake of [18F] FLT may guide stereotactic biopsy but does not discriminate between grade II and III glioma. b) [18F] FLT uptake and texture parameters correlate with overall survival (OS) in newly diagnosed gliomas. c) In patients with recurrent glioma, proliferative volume (PV) and tumour-to-normal brain (T/N) uptake ratio are independent predictors of survival. d) Patients demonstrating response to therapy at [18F] FLT PET scan show longer OS compared to non-responders. e) [18F] FLT PET demonstrated good performance in discriminating tumour recurrence from radionecrosis. However, controversial results exist in comparative literature examining the performance of [18F] FLT vs. other radiotracers in the assessment of recurrence. CONCLUSION [18F] FLT PET imaging has demonstrated potential benefits for grading, diagnostic and prognostic purposes, despite the small sample size studies due to the relatively low availability of the radiotracer.
Collapse
Affiliation(s)
| | - Natale Quartuccio
- Nuclear Medicine Unit, A.R.N.A.S. Ospedali Civico Di Cristina Benfratelli, Italy
| | - Virginia Rossetti
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Monica Celli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Pierpaolo Alongi
- Nuclear Medicine Unit, Fondazione Istituto G. Giglio, Ct. da Pietra Pollastra-pisciotto, Cefalù. Italy
| | - Michele Boero
- Nuclear Medicine Unit, AO Brotzu, 09134 Cagliari, Italy
| | - Gaspare Arnone
- Nuclear Medicine Unit, A.R.N.A.S. Ospedali Civico Di Cristina Benfratelli, Italy
| | - Sergio Baldari
- Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy
| | - Federica Matteucci
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Riccardo Laudicella
- Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, Italy
| |
Collapse
|
19
|
Feliciani G, Celli M, Ferroni F, Matteucci F, Barone D, Paganelli G, Sarnelli A. Investigation of 68-Ga PSMA PET and multiparametric MRI imaging radiomics based models in the prediction of ISUP score in prostate cancer patients. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00219-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
20
|
Belli M, Mezzenga E, Cesarini F, Caroli P, Di Iorio V, Cremonesi M, Strigari L, Romeo A, Nicolini S, Matteucci F, Severi S, Paganelli G, Sarnelli A. Targeted alpha PSMA-based therapy of metastatic castrate-resistant prostate-cancer patients (mCRPC): prediction dosimetry. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00055-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
21
|
Belli M, Mezzenga E, Cesarini F, Caroli P, Di Iorio V, Cremonesi M, Strigari L, Romeo A, Nicolini S, Matteucci F, Severi S, Paganelli G, Sarnelli A. Targeted alpha PSMA-based therapy of metastatic castrate-resistant prostate-cancer patients (mCRPC): prediction dosimetry. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00188-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
22
|
Celli M, Caroli P, Amadori E, Arpa D, Gurrieri L, Ghigi G, Cenni P, Paganelli G, Matteucci F. Diagnostic and Prognostic Potential of 18F-FET PET in the Differential Diagnosis of Glioma Recurrence and Treatment-Induced Changes After Chemoradiation Therapy. Front Oncol 2021; 11:721821. [PMID: 34671551 PMCID: PMC8521061 DOI: 10.3389/fonc.2021.721821] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Accepted: 09/09/2021] [Indexed: 11/24/2022] Open
Abstract
Background MRI-based differential diagnosis of glioma recurrence (GR) and treatment-induced changes (TICs) remain elusive in up to 30% of treated glioma patients. We aimed to determine 18F-FET PET diagnostic performance in this clinical scenario, its outcome dependency on established prognostic factors, optimal 18F-FET semi-quantitative thresholds, and whether 18F-FET parameters may instantly predict progression-free survival (PFS) and overall survival (OS). Methods We retrospectively analyzed 45 glioma patients treated with chemoradiation therapy (32 males; mean age: 51 years, glioma grade: n=26 WHO4; n=15 WHO3; n=4 WHO2) who underwent 18F-FET PET to resolve differential diagnosis of GR and TICs raised by MRI performed in the preceding 2 weeks and depicting any of the following changes in their radiation field: volumetric increase of contrast-enhancing lesions; new contrast-enhancing lesion; significant increase in T2/FLAIR non-enhancing lesion without reducing corticosteroids. 18F-FET PET outcome relied on evaluation of maximum tumor-to-brain ratio (TBRmax), time-to-peak (TTP), and time-activity curve pattern (TAC). Metabolic tumor volume (MTV) and total tumor metabolism (TTM) were calculated for prognostic purposes. Standard of reference was repeat MRI performed 4–6 weeks after the previous MRI. Non-parametric statistics tested 18F-FET-based parameters for dependency on established prognostic markers. ROC curve analysis determined optimal cutoff values for 18F-FET semi-quantitative parameters. 18F-FET parameters and prognostic factors were evaluated for PFS and OS by Kaplan-Meier, univariate, and multivariate analyses. Results 18F-FET PET sensitivity, specificity, positive predictive value, negative predictive value were 86.2, 81.3, 89.3, 76.5%, respectively; higher diagnostic accuracy was yielded in IDH-wild-type glioma patients compared to IDH-mutant glioma patients (sensitivity: 81.8 versus 88.9%; specificity: 80.8 versus 81.8%). KPS was the only prognostic factor differing according to 18F-FET PET outcome (negative versus positive). Optimal 18F-FET cutoff values for GR were TBRmax ≥ 2.1, SUVmax ≥ 3.5, and TTP ≤ 29 min. PFS differed based on 18F-FET outcome and related metrics and according to KPS; a different OS was observed according to KPS only. On multivariate analysis, 18F-FET PET outcome was the only significant PFS factor; KPS and age the only significant OS factors. Conclusion 18F-FET PET demonstrated good diagnostic performance. 18F-FET PET outcome and metrics were significantly predictive only for PFS.
Collapse
Affiliation(s)
- Monica Celli
- Diagnostic Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Paola Caroli
- Diagnostic Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Elena Amadori
- Radiology MRI Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Donatella Arpa
- Radiation Therapy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Lorena Gurrieri
- Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Giulia Ghigi
- Radiation Therapy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Patrizia Cenni
- Radiology MRI Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Giovanni Paganelli
- Diagnostic Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Federica Matteucci
- Diagnostic Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| |
Collapse
|
23
|
Conteduca V, Scarpi E, Wetterskog D, Brighi N, Ferroni F, Rossi A, Romanel A, Gurioli G, Bleve S, Gianni C, Schepisi G, Lolli C, Cortesi P, Matteucci F, Barone D, Paganelli G, Demichelis F, Beltran H, Attard G, De Giorgi U. Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. Int J Cancer 2021; 150:1166-1173. [PMID: 34605002 DOI: 10.1002/ijc.33834] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 09/20/2021] [Accepted: 09/22/2021] [Indexed: 11/12/2022]
Abstract
Cancer is a risk factor for venous thromboembolism (VTE). Plasma tumor DNA (ptDNA) is an independent predictor of outcome in metastatic castration-resistant prostate cancer (mCRPC). We aimed to investigate the association between ptDNA and VTE in mCRPC. This prospective biomarker study included 180 mCRPC patients treated with abiraterone and enzalutamide from April 2013 to December 2018. We excluded patients with a previous VTE history and/or ongoing anticoagulation therapy. Targeted next-generation sequencing was performed to determine ptDNA fraction from pretreatment plasma samples. VTE risk based on survival analysis was performed using cumulative incidence function and estimating sub-distributional hazard ratio (SHR). At a median follow-up of 58 months (range 0.5-111.0), we observed 21 patients who experienced VTE with a cumulative incidence at 12 months of 17.1% (95% confidence interval [CI] 10.3-23.9). Elevated ptDNA, visceral metastasis, prior chemotherapy and lactate dehydrogenase (LDH) were significantly associated with higher VTE incidence compared to patients with no thrombosis (12-month estimate, 18.6% vs 3.5%, P = .0003; 44.4% vs 14.8%, P = .015; 24.7% vs 4.5%, P = .006; and 30.0% vs 13.5%, P = .05, respectively). In the multivariate analysis including ptDNA level, visceral metastases, number of lesions and serum LDH, high ptDNA fraction was the only independent factor associated with the risk of thrombosis (HR 5.78, 95% CI 1.63-20.44, P = .006). These results first suggest that baseline ptDNA fraction in mCRPC patients treated with abiraterone or enzalutamide may be associated with increased VTE risk. These patients may be followed-up more closely for the VTE risk, and the need for a primary thromboprophylaxis should be taken into account in mCRPC with elevated ptDNA.
Collapse
Affiliation(s)
- Vincenza Conteduca
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.,Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy
| | - Emanuela Scarpi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | | | - Nicole Brighi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Fabio Ferroni
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Alice Rossi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Alessandro Romanel
- Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy
| | - Giorgia Gurioli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Sara Bleve
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Caterina Gianni
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Giuseppe Schepisi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Cristian Lolli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Pietro Cortesi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Federica Matteucci
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Domenico Barone
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Giovanni Paganelli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Francesca Demichelis
- Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy
| | - Himisha Beltran
- Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
| | | | - Ugo De Giorgi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| |
Collapse
|
24
|
De Giorgi U, Conteduca V, Gurioli G, Matteucci F, Paganelli G. Targeted radioactive therapy for prostate cancer. Lancet 2021; 398:487-488. [PMID: 34364517 DOI: 10.1016/s0140-6736(21)01336-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2021] [Accepted: 04/30/2021] [Indexed: 10/20/2022]
Affiliation(s)
- Ugo De Giorgi
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori-IRST-Dino Amadori, 47014 Meldola, Italy.
| | - Vincenza Conteduca
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori-IRST-Dino Amadori, 47014 Meldola, Italy
| | - Giorgia Gurioli
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori-IRST-Dino Amadori, 47014 Meldola, Italy
| | - Federica Matteucci
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori-IRST-Dino Amadori, 47014 Meldola, Italy
| | - Giovanni Paganelli
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori-IRST-Dino Amadori, 47014 Meldola, Italy
| |
Collapse
|
25
|
Fantini L, Belli ML, Azzali I, Loi E, Bettinelli A, Feliciani G, Mezzenga E, Fedeli A, Asioli S, Paganelli G, Sarnelli A, Matteucci F. Exploratory Analysis of 18F-3'-deoxy-3'-fluorothymidine ( 18F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer. Front Oncol 2021; 11:601053. [PMID: 34249671 PMCID: PMC8264651 DOI: 10.3389/fonc.2021.601053] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Accepted: 05/31/2021] [Indexed: 01/06/2023] Open
Abstract
Purpose The objective of this study was to evaluate a set of radiomics-based advanced textural features extracted from 18F-FLT-PET/CT images to predict tumor response to neoadjuvant chemotherapy (NCT) in patients with locally advanced breast cancer (BC). Materials and Methods Patients with operable (T2-T3, N0-N2, M0) or locally advanced (T4, N0-N2, M0) BC were enrolled. All patients underwent chemotherapy (six cycles every 3 weeks). Surgery was performed within 4 weeks of the end of NCT. The MD Anderson Residual Cancer Burden calculator was used to evaluate the pathological response. 18F-FLT-PET/CT was performed 2 weeks before the start of NCT and approximately 3 weeks after the first cycle. The evaluation of PET response was based on EORTC criteria. Standard uptake value (SUV) statistics (SUVmax, SUVpeak, SUVmean), together with 148 textural features, were extracted from each lesion. Indices that are robust against contour variability (ICC test) were used as independent variables to logistically model tumor response. LASSO analysis was used for variable selection. Results Twenty patients were included in the study. Lesions from 15 patients were evaluable and analyzed: 9 with pathological complete response (pCR) and 6 with pathological partial response (pPR). Concordance between PET response and histological examination was found in 13/15 patients. LASSO logistic modelling identified a combination of SUVmax and the textural feature index IVH_VolumeIntFract_90 as the most useful to classify PET response, and a combination of PET response, ID range, and ID_Coefficient of Variation as the most useful to classify pathological response. Conclusions Our study suggests the potential usefulness of FLT-PET for early monitoring of response to NCT. A model based on PET radiomic characteristics could have good discriminatory capacity of early response before the end of treatment.
Collapse
Affiliation(s)
- Lorenzo Fantini
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
| | - Maria Luisa Belli
- Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
| | - Irene Azzali
- Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
| | - Emiliano Loi
- Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
| | - Andrea Bettinelli
- Medical Physics Department, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Giacomo Feliciani
- Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
| | - Emilio Mezzenga
- Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
| | - Anna Fedeli
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
| | - Silvia Asioli
- Pathology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy
| | - Giovanni Paganelli
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
| | - Anna Sarnelli
- Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
| | - Federica Matteucci
- Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy
| |
Collapse
|
26
|
Di Iorio V, Boschi S, Sarnelli A, Cuni C, Bianchini D, Monti M, Gorgoni G, Paganelli G, Matteucci F, Masini C. [ 18F]F-PSMA-1007 Radiolabelling without an On-Site Cyclotron: A Quality Issue. Pharmaceuticals (Basel) 2021; 14:ph14070599. [PMID: 34206461 PMCID: PMC8308622 DOI: 10.3390/ph14070599] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Revised: 06/10/2021] [Accepted: 06/15/2021] [Indexed: 12/20/2022] Open
Abstract
Radiopharmaceuticals targeting the prostate-specific membrane antigen (PSMA) has become the gold standard for PET imaging of prostate cancer. [68Ga]Ga-PSMA-11 has been the forerunner but a [18F]F-PSMA ligand has been developed because of the intrinsic advantages of Fluorine-18. Fluorine-18 labelled compounds are usually prepared in centers with an on-site cyclotron. Since our center has not an on-site cyclotron, we decided to verify the feasibility of producing the experimental 18F-labelled radiopharmaceutical [18F]F-PSMA-1007 with [18F]F- from different external suppliers. A quality agreement has been signed with two different suppliers, and a well-established and correctly implemented quality assurance protocol has been followed. The [18F]F- was produced with cyclotrons, on Nb target, but with different beam energy and current. Extensive validation of the [18F]F-PSMA-1007 synthesis process has been performed. The aim of this paper was the description of all the quality documentation which allowed the submission and approval of the Investigational Medicinal Product Dossier (IMPD) to the Competent Authority, addressing the quality problems due to different external suppliers. The result indicates that no significant differences have been found between the [18F]F- from the two suppliers in terms of radionuclidic and radiochemical purity and [18F]F- impacted neither the radiochemical yield of the labelling reaction nor the quality control parameters of the IMP [18F]F-PSMA-1007. These results prove how a correct quality assurance system can overcome some Regulatory Authorities issue that may represent an obstacle to the clinical use of F-18-labelled radiopharmaceuticals without an on-site cyclotron.
Collapse
Affiliation(s)
- Valentina Di Iorio
- IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” IRST, 47014 Meldola, Italy; (A.S.); (C.C.); (D.B.); (M.M.); (G.P.); (F.M.); (C.M.)
- Correspondence: ; Tel.: +39-0543-739930
| | - Stefano Boschi
- Department for Life Quality Studies, University of Bologna, 47921Rimini, Italy;
| | - Anna Sarnelli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” IRST, 47014 Meldola, Italy; (A.S.); (C.C.); (D.B.); (M.M.); (G.P.); (F.M.); (C.M.)
| | - Cristina Cuni
- IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” IRST, 47014 Meldola, Italy; (A.S.); (C.C.); (D.B.); (M.M.); (G.P.); (F.M.); (C.M.)
| | - David Bianchini
- IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” IRST, 47014 Meldola, Italy; (A.S.); (C.C.); (D.B.); (M.M.); (G.P.); (F.M.); (C.M.)
| | - Manuela Monti
- IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” IRST, 47014 Meldola, Italy; (A.S.); (C.C.); (D.B.); (M.M.); (G.P.); (F.M.); (C.M.)
| | - Giancarlo Gorgoni
- Radiopharmacy & Cyclotron Department, IRCCS Ospedale Sacro Cuore-Don Calabria, 37024 Negrar di Valpolicella, Italy;
| | - Giovanni Paganelli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” IRST, 47014 Meldola, Italy; (A.S.); (C.C.); (D.B.); (M.M.); (G.P.); (F.M.); (C.M.)
| | - Federica Matteucci
- IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” IRST, 47014 Meldola, Italy; (A.S.); (C.C.); (D.B.); (M.M.); (G.P.); (F.M.); (C.M.)
| | - Carla Masini
- IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” IRST, 47014 Meldola, Italy; (A.S.); (C.C.); (D.B.); (M.M.); (G.P.); (F.M.); (C.M.)
| |
Collapse
|
27
|
Tumedei MM, Ravaioli S, Matteucci F, Celli M, De Giorgi U, Gunelli R, Puccetti M, Paganelli G, Bravaccini S. Spotlight on PSMA as a new theranostic biomarker for bladder cancer. Sci Rep 2021; 11:9777. [PMID: 33963223 PMCID: PMC8105396 DOI: 10.1038/s41598-021-89160-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Accepted: 04/14/2021] [Indexed: 12/24/2022] Open
Abstract
Bladder cancer (BCa) patients are diagnosed by cytology and cystoscopy. However, these diagnostic tests bear some limitations. We sought for reliable biomarkers to better determine BCa extension. Prostate-specific membrane antigen (PSMA) appears to fulfill this requirement in prostate cancer but its role in BCa has not been established yet. We then analyzed 87 bladder tissue samples from 74 patients assessing PSMA expression by immunohistochemistry. The median PSMA expression, exclusively found in tumor neovasculature, in terms of H-score significantly differed between non-tumor samples and tumor samples (p = 0.00288) showing a higher neovasculature-related PSMA expression. No differences were observed in relation to tumor type, grade and stage. BCa neovasculature-related PSMA overexpression may be useful in defining the degree of extension of the neoplasm. In addition, testing PSMA expression by immunohistochemistry may hold theranostic implications both considering anti-angiogenesis agents and radio-labelled PSMA ligands for intracavitary radionuclide therapy. In our opinion, BCa neovasculature-related PSMA overexpression may be considered an apt target for anti-angiogenesis and radionuclide treatment in BCa, once the evaluation of tumor-retention time for the appropriateness of long half-life therapeutic PSMA ligands as radionuclide treatment will be performed.
Collapse
Affiliation(s)
- Maria Maddalena Tumedei
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Sara Ravaioli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, Italy.
| | - Federica Matteucci
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Monica Celli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Ugo De Giorgi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Roberta Gunelli
- Department of Urology, Morgagni Pierantoni Hospital, Forli, Italy
| | | | - Giovanni Paganelli
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Sara Bravaccini
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, Italy
| |
Collapse
|
28
|
Conteduca V, Poti G, Caroli P, Russi S, Brighi N, Lolli C, Schepisi G, Romeo A, Matteucci F, Paganelli G, Marchetti P, De Giorgi U. Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. Ther Adv Med Oncol 2021; 13:1758835920987654. [PMID: 33708265 PMCID: PMC7907710 DOI: 10.1177/1758835920987654] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2020] [Accepted: 12/17/2020] [Indexed: 12/17/2022] Open
Abstract
Over the years, an increasing proportion of metastatic prostate cancer patients has been found to experience an initial bone flare phenomenon under both standard therapies (androgen deprivation therapy, chemotherapy, radiotherapy, abiraterone, enzalutamide) and novel agents (immunotherapy, bone-targeting radioisotopes). The underlying biological mechanisms of the flare phenomenon are still elusive and need further clarification, particularly in relation to different types of treatment and their treatment response assessment. Flare phenomenon is often underestimated and, in some cases, can negatively affect clinical outcome. In cases with suspected bone flare, the treatment should be continued for a minimum of 12 more weeks before further decisions about efficacy can be taken. Physicians and patients should be aware of this effect to avoid unwarranted anxiety and inadequate early discontinuation of treatment. This review aims at highlighting new evidence on flare phenomenon arising after the introduction of new drugs extending across the biochemical, radiographic and clinical spectrum of the disease.
Collapse
Affiliation(s)
- Vincenza Conteduca
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori" (IRST), IRCCS, Via Piero Maroncelli 40, Meldola (FC), Emilia-Romagna 47014, Italy
| | - Giulia Poti
- Department of Clinical and Molecular Medicine, University "La Sapienza", Rome, Lazio, Italy
| | - Paola Caroli
- Department of Nuclear Medicine, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori" (IRST), IRCCS, Meldola, Emilia-Romagna, Italy
| | - Sabino Russi
- Laboratory of Preclinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata (CROB), Rionero in Vulture (PZ), Italy
| | - Nicole Brighi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori" (IRST), IRCCS, Meldola, Emilia-Romagna, Italy
| | - Cristian Lolli
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori" (IRST), IRCCS, Meldola, Emilia-Romagna, Italy
| | - Giuseppe Schepisi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori" (IRST), IRCCS, Meldola, Emilia-Romagna, Italy
| | - Antonino Romeo
- Department of Radiotherapy,Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori" (IRST), IRCCS, Meldola, Italy
| | - Federica Matteucci
- Department of Nuclear Medicine, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori" (IRST), IRCCS, Meldola, Emilia-Romagna, Italy
| | - Giovanni Paganelli
- Department of Nuclear Medicine, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori" (IRST), IRCCS, Meldola, Emilia-Romagna, Italy
| | - Paolo Marchetti
- Department of Clinical and Molecular Medicine, University "La Sapienza", Rome, Lazio, Italy
| | - Ugo De Giorgi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori "Dino Amadori" (IRST), IRCCS, Meldola, Emilia-Romagna, Italy
| |
Collapse
|
29
|
Conteduca V, Scarpi E, Wetterskog D, Caroli P, Romanel A, Lolli C, Jayaram A, Gurioli G, Brighi N, Poti G, Wingate A, Schepisi G, Matteucci F, Paganelli G, Demichelis F, Attard G, De Giorgi U. Combining molecular and functional imaging in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.6_suppl.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
141 Background: Recently, plasma tumour DNA (ptDNA) has been identified as a potential early noninvasive biomarker of treatment response in mCRPC patients ( Conteduca, Br J Cancer 2020). In this study, we sought to determine whether pre-treatment ptDNA could accurately reflect metabolic tumor burden in mCRPC and if it could be in combination with functional imaging could provide better prognostication. Methods: Between October 2011 and June 2016, 102 plasma samples from mCRPC patients treated with abiraterone or enzalutamide were collected. Targeted next-generation sequencing was performed to determine baseline ptDNA fraction. Maximum standardized uptake value (SUVmax), total lesion activity (TLA), and metabolic tumour volume (MTV) were calculated on 18F-fluorocholine positron emission tomography/computed tomography. A Weibull multiple regression model was adopted to evaluate the combined impact of clinical, molecular and imaging features on overall survival (OS) and to obtain a prognostic score. Each variable was allotted a “partial score” that depended on the size of the regression coefficient. Total scores ranged between 0 and 5.85 and assigned patients to 3 different risk groups according to 18-months survival probability: group I, >70%; group II 30%-70%; and group III, <30%. We estimated OS probabilities by the exponential model and by the Kaplan-Meier method. Results: We observed a significant association between ptDNA levels dichotomized as below or above median plasma tumor fraction (low ptDNA≤0.188 versus high ptDNA>0.188) and median SUVmax (p<0.0001), MTV (p=0.0005) and TLA (p<0.0001). Patients were randomly divided into a training set (n=68) and a validation set (n=34). In the training cohort, we performed a multivariable analysis showing that visceral metastasis, serum LDH, MTV and ptDNA were independent predictors of OS [HR=2.64, 95%CI 1.32-5.26, p=0.006; HR=3.69, 95%CI 1.98-6.87, p<0.0001; HR=1.91, 95%CI 1.13-3.21, p=0.015; and HR=2.64, 95%CI 1.32-5.26, p=0.003, respectively]. In the training set, median OS was significantly different among the 3 risk groups (risk group I, 29.2 months [95% CI, 18.3 to 37.0 months]; risk group II, 15.9 months [95% CI, 10.6 to 24.0 months]; and risk group III, 8.7 months [95% CI, 6.3 to 15.4 months]; p<0.0001). Similar results were observed in the validation set groups (risk group I, 23.4 months [95% CI, 8.1 to 38.5 months]; risk group II, 13.3 months [95% CI, 3.7 to 18.0 months]; and risk group III, 7.3 months [95% CI, 2.6 to 11.8 months]; p=0.001). Conclusions: Integrating plasma DNA analysis with functional imaging may improve prognostic risk stratification and treatment selection in mCRPC patients. A larger prospective evaluation is now warranted.
Collapse
Affiliation(s)
- Vincenza Conteduca
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy
| | - Emanuela Scarpi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | | | | | | | - Cristian Lolli
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Anuradha Jayaram
- University College London Cancer Institute, London, United Kingdom
| | - Giorgia Gurioli
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Nicole Brighi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy
| | - Giulia Poti
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Anna Wingate
- University College London, London, United Kingdom
| | - Giuseppe Schepisi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | | | - Giovanni Paganelli
- Scientific Institute of Romagna for the Study and Treatment of Tumors (IRST), UOC Nuclear Medicine, Meldola, Italy
| | - Francesca Demichelis
- Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy
| | - Gerhardt Attard
- Institute of Cancer Research and The Royal Marsden Hospital, Sutton, United Kingdom
| | - Ugo De Giorgi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Meldola, Italy
| |
Collapse
|
30
|
Rocca A, Cortesi P, Cortesi L, Gianni L, Matteucci F, Fantini L, Maestri A, Giunchi DC, Cavanna L, Ciani R, Falcini F, Bagni A, Meldoli E, Dall’Agata M, Volpi R, Andreis D, Nanni O, Curcio A, Lucchi L, Amadori D, Fedeli A. Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer. Ther Adv Med Oncol 2021; 13:1758835920985632. [PMID: 33613693 PMCID: PMC7876584 DOI: 10.1177/1758835920985632] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Accepted: 12/11/2020] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND The aim of this study was to improve activity over single human epidermal growth factor receptor 2 (HER2)-blockade sequential neaodjuvant regimens for HER2-positive breast cancer, by exploiting the concomitant administration of trastuzumab, taxane and anthracycline, while restraining cardiac toxicity with use of liposomal doxorubicin, and by adding metformin, based on preliminary evidence of antitumor activity. PATIENTS AND METHODS This multi-center, single-arm, two-stage phase II trial, assessed the safety and the activity of a new treatment regimen for HER2-positive, early or locally advanced breast cancer. Patients received six 21-day cycles of non-pegylated liposomal doxorubicin, 50 mg/m2 intravenously (i.v.) on day 1, docetaxel, 30 mg/m2 i.v. on days 2 and 9, trastuzumab, 2 mg/kg/week i.v. on days 2, 9, and 16 (with 4 mg/kg loading dose), in association with metformin 1000 mg orally twice daily. The primary endpoint was the rate of pathological complete response (pCR) in the breast and axilla (ypT0/is ypN0). A subgroup of patients performed a 3-deoxy-3-18F-fluorothymidine positron emission tomography (FLT-PET) at baseline and after one cycle. RESULTS Among 47 evaluable patients, there were 18 pCR [38.3%, 95% confidence interval (CI) 24.5-53.6%]. A negative estrogen-receptor status, high Ki67, and histological grade 3 were related with pCR, although only grade reached statistical significance. FLT-PET maximum standardized uptake value after one cycle was inversely related to pCR in the breast (odds ratio 0.29, 95% CI 0.06-1.30, p = 0.11). Toxicity included grade 3-4 neutropenia in 70% and febrile neutropenia in 4% of patients, grade 1-2 nausea/vomiting in 60%/38%, and grade 3 in 4%/2%, respectively, grade 1-2 diarrhea in 72%, and grade 3 in 6%. There were two cases of reversible grade 2 left-ventricular ejection-fraction decrease, and one case of sharp troponin-T increase. CONCLUSIONS The concomitant administration of trastuzumab, liposomal doxorubicin, docetaxel, and metformin is safe and shows good activity, but does not appear to improve activity over conventional sequential regimens.
Collapse
Affiliation(s)
- Andrea Rocca
- Department of Clinical and Experimental Oncology and Hematology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Maroncelli 40, Meldola 47014, Italy
| | - Pietro Cortesi
- Department of Clinical and Experimental Oncology and Hematology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Laura Cortesi
- Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy
| | - Lorenzo Gianni
- Department of Medical Oncology, Infermi Hospital, Rimini, Italy
| | - Federica Matteucci
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Lorenzo Fantini
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Antonio Maestri
- Department of Medical Oncology, Santa Maria della Scaletta Hospital, Imola, Italy
| | - Donata Casadei Giunchi
- Department of Clinical and Experimental Oncology and Hematology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Luigi Cavanna
- Department of Onco-Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy
| | - Rosa Ciani
- Cancer Prevention Unit, Azienda Usl della Romagna, Forlì, Italy
| | - Fabio Falcini
- Cancer Prevention Unit, Azienda Usl della Romagna, Forlì, Italy Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Antonella Bagni
- Breast Diagnostic Unit, Maurizio Bufalini Hospital, Cesena, Italy
| | - Elena Meldoli
- Breast Diagnostic Unit, Maurizio Bufalini Hospital, Cesena, Italy
| | - Monia Dall’Agata
- Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Roberta Volpi
- Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Daniele Andreis
- Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Oriana Nanni
- Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Annalisa Curcio
- Breast Surgery Unit, Morgagni-Pierantoni Hospital, Forlì, Italy
| | - Leonardo Lucchi
- Breast Surgery Unit, Maurizio Bufalini Hospital, Forlì, Italy
| | - Dino Amadori
- Department of Clinical and Experimental Oncology and Hematology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Anna Fedeli
- Department of Clinical and Experimental Oncology and Hematology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| |
Collapse
|
31
|
Abstract
Recent advances in the diagnosis and treatment of multiple myeloma (MM) have highlighted the importance of imaging methods, not only in the localization and extent of the disease but also in prognostic stratification and assessment of response to therapy. In this context, PET/CT, combining both morphological and functional information, is particularly useful in this pathology. The tracer mostly used is 18F-FDG, a glucose analog, which provides extremely accurate information with a sensitivity ranging from 80 to 100%. However, this tracer has some limitations, mostly related to the physiological uptake of FDG in the bone marrow and brain, which reduce its effectiveness. For this reason, some studies in the literature have evaluated the effectiveness of other PET tracers, which provide information on protein metabolism or the synthesis of metabolic plasma membranes, such as choline and methionine, as well as innovative radiopharmaceuticals, directed against receptors expressed by cells of myeloma, including tracers directed to the chemokine receptor. This review analyzes the characteristics and accuracy of non-FDG tracers in the management of patients with multiple myeloma.
Collapse
Affiliation(s)
- Federica Matteucci
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (IRST) IRCCS, Meldola, Italy
| | - Giovanni Paganelli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (IRST) IRCCS, Meldola, Italy
| | - Giovanni Martinelli
- Hematology Unit, Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (IRST) IRCCS, Meldola, Italy
| | - Claudio Cerchione
- Hematology Unit, Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (IRST) IRCCS, Meldola, Italy
| |
Collapse
|
32
|
Paganelli G, Matteucci F. Importance of PET with 68Ga-Labeled Somatostatin Analogs (perspective on “ 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT” J Nucl Med. 2007;48:508–518). J Nucl Med 2020; 61:187S-188S. [DOI: 10.2967/jnumed.120.254631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Accepted: 08/19/2020] [Indexed: 11/16/2022] Open
|
33
|
Caroli P, Colangione SP, De Giorgi U, Ghigi G, Celli M, Scarpi E, Monti M, Di Iorio V, Sarnelli A, Paganelli G, Matteucci F, Romeo A. 68Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy. Biomedicines 2020; 8:biomedicines8120536. [PMID: 33255681 PMCID: PMC7761444 DOI: 10.3390/biomedicines8120536] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Revised: 11/18/2020] [Accepted: 11/23/2020] [Indexed: 12/15/2022] Open
Abstract
(1) Purpose: To investigate the role of 68Ga-PSMA-11 PET/CT in guiding retreatment stereotactic body radiation therapy (SBRT) in prostate cancer (PCa) patients in biochemical recurrence (BCR) after salvage radiotherapy (S-RT). (2) Methods: We retrospectively evaluated PCa patients previously treated with S-RT on the prostate bed and with proven serum prostate antigen (PSA) failure after S-RT. In all patients (pts), 68Ga-PSMA-11 PET/CT was positive in the prostate bed only and guided retreatment SBRT. All retreatments were performed by applying the same radiotherapy protocol (median dose of 18 Gy/3 fractions; IQR 18-21 Gy). The median follow-up was 27 months (range 4-35 months). (3) Results: 38 consecutive patients were considered in this analysis. The overall median PSA level before RT was 1.10 ng/mL (IQR 0.82-2.59). PSA decreased at 3 and 6 months after treatment, with a median value of 0.60 ng/mL (IQR 0.31-0.96; p < 0.001) and 0.51 ng/mL (IQR 0.29-1.17; p < 0.001), respectively. Overall, biochemical recurrence-free survival (b-RFS) was 15.0 months (95% CI 13-23). Grade-1 toxicity was reported in 31.6% of patients (12/38). (4) Conclusion: These results confirm that 68Ga-PSMA-11-PET/CT is able to identify the site of recurrence in patients who have failed S-RT, thus supporting the use of metastases-directed radiotherapy as a safe and effective treatment.
Collapse
Affiliation(s)
- Paola Caroli
- Unit of Nuclear Medicine, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (P.C.); (M.C.); (G.P.)
| | - Sarah Pia Colangione
- Department of Radiotherapy, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (S.P.C.); (G.G.); (A.R.)
| | - Ugo De Giorgi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy;
| | - Giulia Ghigi
- Department of Radiotherapy, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (S.P.C.); (G.G.); (A.R.)
| | - Monica Celli
- Unit of Nuclear Medicine, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (P.C.); (M.C.); (G.P.)
| | - Emanuela Scarpi
- Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, Via Maroncelli 40, 47014 Meldola, Italy; (E.S.); (M.M.)
| | - Manuela Monti
- Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, Via Maroncelli 40, 47014 Meldola, Italy; (E.S.); (M.M.)
| | - Valentina Di Iorio
- Oncology Pharmacy, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy;
| | - Anna Sarnelli
- Unit of Medical Physics, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy;
| | - Giovanni Paganelli
- Unit of Nuclear Medicine, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (P.C.); (M.C.); (G.P.)
| | - Federica Matteucci
- Unit of Nuclear Medicine, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (P.C.); (M.C.); (G.P.)
- Correspondence:
| | - Antonino Romeo
- Department of Radiotherapy, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (S.P.C.); (G.G.); (A.R.)
| |
Collapse
|
34
|
Belli ML, Sarnelli A, Mezzenga E, Cesarini F, Caroli P, Di Iorio V, Strigari L, Cremonesi M, Romeo A, Nicolini S, Matteucci F, Severi S, Paganelli G. Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen). Front Oncol 2020; 10:531660. [PMID: 33251129 PMCID: PMC7674768 DOI: 10.3389/fonc.2020.531660] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Accepted: 08/20/2020] [Indexed: 01/17/2023] Open
Abstract
Radioligand therapy is a type of internal radiotherapy combining a short-range radioisotope labeled to a carrier with a high affinity for a specific receptor expressed on tumor cells. Targeted alpha therapy (TAT) combines a high-linear energy transfer (LET) emitter (225Ac) with a prostate-specific membrane antigen (PSMA) carrier, specifically binding tumor cells in patients with metastatic castration-resistant prostate cancer. Although the antitumor activity of 225Ac-PSMA is well-documented, this treatment is nowadays only used as salvage therapy because the high incidence of xerostomia limits the therapeutic window. Thus, methods to reduce salivary toxicity and models able to describe xerostomia incidence are needed. We recently studied the efficacy of salivary gland protectors administered in combination with 177Lu-PSMA therapy. Starting from these data, we performed a predictive dosimetric evaluation of 225Ac-PSMA to assess the impact of salivary gland protectors in TAT. 225Ac-PSMA predictive dosimetry was performed in 13 patients treated with 177Lu-PSMA. Sequential whole-body planar images were acquired 0.5–1, 16–24, 36–48, and 120 h post-injection. 177Lu time-activity curves were corrected for 225Ac physical decay and assumed in equilibrium for all daughters. The OLINDA/EXM spherical model was used for dose estimation of the parotid and submandibular glands. The dose for each daughter was calculated and summed for the total dose estimation. The biologically effective dose formalism was extended to high-LET emitters. For the total biologically effective dose formalism extended to high-LET emitters, including the contribution of all daughter isotopes, the brachytherapy formalism for a mixture of radionuclides was implemented. Equivalent doses in 2 Gy/fraction (EQD2) were then calculated and compared with the normal tissue complication probability model derived from external beam radiotherapy for grade ≥2 xerostomia induction. Median predictive doses were 0.86 BdRBE5/MBq for parotid glands and 1.05 BdRBE5/MBq for submandibular glands, with a 53% reduction compared with previously published data. The results show that the radiobiological model implemented is conservative, as it overestimates the complication rate with respect to the clinical data. Our data shows the possibility of reducing salivary gland uptake in TAT with the coadministration of organ protectors, but these results should be confirmed for TAT with 225Ac-PSMA by carrying out prospective trials with defined toxicity endpoints and dosimetry procedures.
Collapse
Affiliation(s)
- Maria Luisa Belli
- Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Anna Sarnelli
- Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Emilio Mezzenga
- Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Francesco Cesarini
- Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Paola Caroli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Valentina Di Iorio
- Oncology Pharmacy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Lidia Strigari
- Medical Physics Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy
| | - Marta Cremonesi
- Radiation Research Unit, European Institute of Oncology (IEO) IRCCS, Milano, Italy
| | - Antonino Romeo
- Radiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Silvia Nicolini
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Federica Matteucci
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Stefano Severi
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Giovanni Paganelli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| |
Collapse
|
35
|
Guerrero C, Lerendegui-Marco J, Paul M, Tessler M, Heinitz S, Domingo-Pardo C, Cristallo S, Dressler R, Halfon S, Kivel N, Köster U, Maugeri EA, Palchan-Hazan T, Quesada JM, Rochman D, Schumann D, Weissman L, Aberle O, Amaducci S, Andrzejewski J, Audouin L, Bécares V, Bacak M, Balibrea J, Barak A, Barbagallo M, Barros S, Bečvář F, Beinrucker C, Berkovits D, Berthoumieux E, Billowes J, Bosnar D, Brugger M, Buzaglo Y, Caamaño M, Calviño F, Calviani M, Cano-Ott D, Cardella R, Casanovas A, Castelluccio DM, Cerutti F, Chen YH, Chiaveri E, Colonna N, Cortés G, Cortés-Giraldo MA, Cosentino L, Dafna H, Damone A, Diakaki M, Dietz M, Dupont E, Durán I, Eisen Y, Fernández-Domínguez B, Ferrari A, Ferreira P, Finocchiaro P, Furman V, Göbel K, García AR, Gawlik A, Glodariu T, Gonçalves IF, González-Romero E, Goverdovski A, Griesmayer E, Gunsing F, Harada H, Heftrich T, Heyse J, Hirsh T, Jenkins DG, Jericha E, Käppeler F, Kadi Y, Kaizer B, Katabuchi T, Kavrigin P, Ketlerov V, Khryachkov V, Kijel D, Kimura A, Kokkoris M, Kriesel A, Krtička M, Leal-Cidoncha E, Lederer-Woods C, Leeb H, Lo Meo S, Lonsdale SJ, Losito R, Macina D, Manna A, Marganiec J, Martínez T, Massimi C, Mastinu P, Mastromarco M, Matteucci F, Mendoza E, Mengoni A, Milazzo PM, Millán-Callado MA, Mingrone F, Mirea M, Montesano S, Musumarra A, Nolte R, Oprea A, Patronis N, Pavlik A, Perkowski J, Piersanti L, Porras I, Praena J, Rajeev K, Rauscher T, Reifarth R, Rodríguez-González T, Rout PC, Rubbia C, Ryan JA, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schmidt S, Shor A, Sedyshev P, Smith AG, Stamatopoulos A, Tagliente G, Tain JL, Tarifeño-Saldivia A, Tassan-Got L, Tsinganis A, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Wallner A, Warren S, Weigand M, Weiss C, Wolf C, Woods PJ, Wright T, Žugec P. Neutron Capture on the s-Process Branching Point ^{171}Tm via Time-of-Flight and Activation. Phys Rev Lett 2020; 125:142701. [PMID: 33064503 DOI: 10.1103/physrevlett.125.142701] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Revised: 07/02/2020] [Accepted: 07/29/2020] [Indexed: 06/11/2023]
Abstract
The neutron capture cross sections of several unstable nuclides acting as branching points in the s process are crucial for stellar nucleosynthesis studies. The unstable ^{171}Tm (t_{1/2}=1.92 yr) is part of the branching around mass A∼170 but its neutron capture cross section as a function of the neutron energy is not known to date. In this work, following the production for the first time of more than 5 mg of ^{171}Tm at the high-flux reactor Institut Laue-Langevin in France, a sample was produced at the Paul Scherrer Institute in Switzerland. Two complementary experiments were carried out at the neutron time-of-flight facility (n_TOF) at CERN in Switzerland and at the SARAF liquid lithium target facility at Soreq Nuclear Research Center in Israel by time of flight and activation, respectively. The result of the time-of-flight experiment consists of the first ever set of resonance parameters and the corresponding average resonance parameters, allowing us to make an estimation of the Maxwellian-averaged cross sections (MACS) by extrapolation. The activation measurement provides a direct and more precise measurement of the MACS at 30 keV: 384(40) mb, with which the estimation from the n_TOF data agree at the limit of 1 standard deviation. This value is 2.6 times lower than the JEFF-3.3 and ENDF/B-VIII evaluations, 25% lower than that of the Bao et al. compilation, and 1.6 times larger than the value recommended in the KADoNiS (v1) database, based on the only previous experiment. Our result affects the nucleosynthesis at the A∼170 branching, namely, the ^{171}Yb abundance increases in the material lost by asymptotic giant branch stars, providing a better match to the available pre-solar SiC grain measurements compared to the calculations based on the current JEFF-3.3 model-based evaluation.
Collapse
Affiliation(s)
- C Guerrero
- Universidad de Sevilla, Seville, Spain
- Centro Nacional de Aceleradores (CNA) (Universidad de Sevilla-Junta de Andalucía-CSIC), Seville, Spain
| | | | - M Paul
- Hebrew University, Jerusalem, Israel
| | - M Tessler
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - S Heinitz
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - C Domingo-Pardo
- Instituto de Física Corpuscular (CSIC-University of Valencia), Valencia, Spain
| | - S Cristallo
- INAF-Osservatorio Astronomico d'Abruzzo, Teramo, Italy
- INFN Sezione Perugia, Perugia, Italy
| | - R Dressler
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - S Halfon
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - N Kivel
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - U Köster
- Institut Laue-Langevin ILL, Grenoble, France
| | - E A Maugeri
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | | | | | - D Rochman
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - D Schumann
- Paul Scherrer Institut (PSI), Villigen, Switzerland
| | - L Weissman
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - O Aberle
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - S Amaducci
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | | | - L Audouin
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, Orsay Cedex, France
| | - V Bécares
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - M Bacak
- Technische Universität Wien, Vienna, Austria
| | - J Balibrea
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A Barak
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - M Barbagallo
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - S Barros
- Instituto Superior Técnico, Lisbon, Portugal
| | - F Bečvář
- Charles University, Prague, Czech Republic
| | | | - D Berkovits
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - E Berthoumieux
- CEA Irfu, Université Paris-Saclay, Gif-sur-Yvette, France
| | - J Billowes
- University of Manchester, Manchester, United Kingdom
| | - D Bosnar
- Department of Physics, Faculty of Science, University of Zagreb, Zagreb, Croatia
| | - M Brugger
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - Y Buzaglo
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - M Caamaño
- University of Santiago de Compostela, Santiago de Conpostela, Spain
| | - F Calviño
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | - M Calviani
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - D Cano-Ott
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - R Cardella
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Casanovas
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | - D M Castelluccio
- Agenzia nazionale per le nuove tecnologie (ENEA), Bologna, Italy
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - F Cerutti
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - Y H Chen
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, Orsay Cedex, France
| | - E Chiaveri
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - N Colonna
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - G Cortés
- Universitat Politècnica de Catalunya, Barcelona, Spain
| | | | - L Cosentino
- INFN Laboratori Nazionali del Sud, Catania, Italy
| | - H Dafna
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - A Damone
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
- Dipartimento di Fisica, Università degli Studi di Bari, Bari, Italy
| | - M Diakaki
- CEA Irfu, Université Paris-Saclay, Gif-sur-Yvette, France
| | - M Dietz
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - E Dupont
- CEA Irfu, Université Paris-Saclay, Gif-sur-Yvette, France
| | - I Durán
- University of Santiago de Compostela, Santiago de Conpostela, Spain
| | - Y Eisen
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | | | - A Ferrari
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - P Ferreira
- Instituto Superior Técnico, Lisbon, Portugal
| | | | - V Furman
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - K Göbel
- Goethe University Frankfurt, Seville, Germany
| | - A R García
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A Gawlik
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - T Glodariu
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Jerusalem, Romania
| | | | - E González-Romero
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A Goverdovski
- Institute of Physics and Power Engineering (IPPE), Obninsk, Russia
| | | | - F Gunsing
- Institut Laue-Langevin ILL, Grenoble, France
- CEA Irfu, Université Paris-Saclay, Gif-sur-Yvette, France
| | - H Harada
- Japan Atomic Energy Agency (JAEA), Tokai-mura, Japan
| | - T Heftrich
- Goethe University Frankfurt, Seville, Germany
| | - J Heyse
- Universitat Politècnica de Catalunya, Barcelona, Spain
- Physikalisch-Technische Bundesanstalt (PTB), Braunschweig, Germany
| | - T Hirsh
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | | | - E Jericha
- Technische Universität Wien, Vienna, Austria
| | - F Käppeler
- Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany
| | - Y Kadi
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - B Kaizer
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | | | - P Kavrigin
- Technische Universität Wien, Vienna, Austria
| | - V Ketlerov
- Institute of Physics and Power Engineering (IPPE), Obninsk, Russia
| | - V Khryachkov
- Institute of Physics and Power Engineering (IPPE), Obninsk, Russia
| | - D Kijel
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - A Kimura
- Japan Atomic Energy Agency (JAEA), Tokai-mura, Japan
| | - M Kokkoris
- National Technical University of Athens, Athens, Greece
| | - A Kriesel
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - M Krtička
- Charles University, Prague, Czech Republic
| | - E Leal-Cidoncha
- University of Santiago de Compostela, Santiago de Conpostela, Spain
| | - C Lederer-Woods
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - H Leeb
- Technische Universität Wien, Vienna, Austria
| | - S Lo Meo
- Agenzia nazionale per le nuove tecnologie (ENEA), Bologna, Italy
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - S J Lonsdale
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - R Losito
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - D Macina
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Manna
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Bologna, Italy
| | | | - T Martínez
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - C Massimi
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Bologna, Italy
| | - P Mastinu
- Istituto Nazionale di Fisica Nucleare, Sezione di Legnaro, Italy
| | - M Mastromarco
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - F Matteucci
- Istituto Nazionale di Fisica Nucleare, Sezione di Trieste, Italy
- Dipartimento di Astronomia, Università di Trieste, Trieste, Italy
| | - E Mendoza
- Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A Mengoni
- Agenzia nazionale per le nuove tecnologie (ENEA), Bologna, Italy
| | - P M Milazzo
- Istituto Nazionale di Fisica Nucleare, Sezione di Trieste, Italy
| | - M A Millán-Callado
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, Orsay Cedex, France
| | - F Mingrone
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - M Mirea
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Jerusalem, Romania
| | - S Montesano
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Musumarra
- INFN Laboratori Nazionali del Sud, Catania, Italy
- Dipartimento di Fisica e Astronomia, Università di Catania, Catania, Italy
| | - R Nolte
- Physikalisch-Technische Bundesanstalt (PTB), Braunschweig, Germany
| | - A Oprea
- Horia Hulubei National Institute of Physics and Nuclear Engineering, Jerusalem, Romania
| | - N Patronis
- University of Ioannina, Ioannina, Greece
| | - A Pavlik
- University of Vienna, Faculty of Physics, Vienna, Austria
| | | | - L Piersanti
- INAF-Osservatorio Astronomico d'Abruzzo, Teramo, Italy
| | - I Porras
- University of Granada, Granada, Spain
| | - J Praena
- Universidad de Sevilla, Seville, Spain
- University of Granada, Granada, Spain
| | - K Rajeev
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - T Rauscher
- Centre for Astrophysics Research, University of Hertfordshire, Hatfield, United Kingdom
- Department of Physics, University of Basel, Basel, Switzerland
| | - R Reifarth
- Goethe University Frankfurt, Seville, Germany
| | - T Rodríguez-González
- Universidad de Sevilla, Seville, Spain
- Centro Nacional de Aceleradores (CNA) (Universidad de Sevilla-Junta de Andalucía-CSIC), Seville, Spain
| | - P C Rout
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - C Rubbia
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - J A Ryan
- University of Manchester, Manchester, United Kingdom
| | - M Sabaté-Gilarte
- Universidad de Sevilla, Seville, Spain
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - A Saxena
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | | | - S Schmidt
- Goethe University Frankfurt, Seville, Germany
| | - A Shor
- Soreq Nuclear Research Center (SNRC), Yavne, Israel
| | - P Sedyshev
- Joint Institute for Nuclear Research (JINR), Dubna, Russia
| | - A G Smith
- University of Manchester, Manchester, United Kingdom
| | | | - G Tagliente
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - J L Tain
- Instituto de Física Corpuscular (CSIC-University of Valencia), Valencia, Spain
| | | | - L Tassan-Got
- Institut de Physique Nucléaire, CNRS-IN2P3, Univ. Paris-Sud, Université Paris-Saclay, Orsay Cedex, France
| | - A Tsinganis
- National Technical University of Athens, Athens, Greece
| | - S Valenta
- Charles University, Prague, Czech Republic
| | - G Vannini
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Bologna, Italy
| | - V Variale
- Istituto Nazionale di Fisica Nucleare, Sezione di Bari, Italy
| | - P Vaz
- Instituto Superior Técnico, Lisbon, Portugal
| | - A Ventura
- Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, Italy
| | - V Vlachoudis
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
| | - R Vlastou
- National Technical University of Athens, Athens, Greece
| | - A Wallner
- Australian National University, Canberra, Australia
| | - S Warren
- University of Manchester, Manchester, United Kingdom
| | - M Weigand
- Goethe University Frankfurt, Seville, Germany
| | - C Weiss
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Technische Universität Wien, Vienna, Austria
| | - C Wolf
- Goethe University Frankfurt, Seville, Germany
| | - P J Woods
- School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
| | - T Wright
- University of Manchester, Manchester, United Kingdom
| | - P Žugec
- European Organization for Nuclear Research (CERN), Geneva, Switzerland
- Department of Physics, Faculty of Science, University of Zagreb, Zagreb, Croatia
| |
Collapse
|
36
|
Pellegrini M, Ercole C, Di Zio C, Matteucci F, Pace L, Del Gallo M. In vitro and in planta antagonistic effects of plant growth-promoting rhizobacteria consortium against soilborne plant pathogens of Solanum tuberosum and Solanum lycopersicum. FEMS Microbiol Lett 2020; 367:5860279. [PMID: 32562424 DOI: 10.1093/femsle/fnaa099] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Accepted: 06/19/2020] [Indexed: 01/07/2023] Open
Abstract
Potatoes (Solanum tuberosum L.) and tomatoes (Solanum lycopersicum L.), among the main crops belonging to the Solanaceae family, are attacked by several pathogens. Among them Fusarium oxysporum f. sp. radicis-lycopersici and Rhizoctonia solani are very common and cause significant losses. Four plant growth-promoting rhizobacteria, Azospirillum brasilense, Gluconacetobacter diazotrophicus, Herbaspirillum seropedicae and Burkholderia ambifaria were tested against these pathogens. In vitro antagonistic activities of single strains were assessed through dual culture plates. Strains showing antagonistic activity (G. diazotrophicus, H. seropedicae and B. ambifaria) were combined and, after an in vitro confirmation, the consortium was applied on S. lycopersicum and S. tuberosum in a greenhouse pot experiment. The bioprotection was assessed in pre-emergence (infection before germination) and post-emergence (infection after germination). The consortium was able to successfully counteract the infection of both F. oxysporum and R. solani, allowing a regular development of plants. The biocontrol of the fungal pathogens was highlighted both in pre-emergence and post-emergence conditions. This selected consortium could be a valid alternative to agrochemicals and could be exploited as biocontrol agent to counteract losses due to these pathogenic fungi.
Collapse
Affiliation(s)
- Marika Pellegrini
- Department of Life, Health and Environmental Sciences, University of L'Aquila, 67010 Coppito, L'Aquila, Italy
| | - Claudia Ercole
- Department of Life, Health and Environmental Sciences, University of L'Aquila, 67010 Coppito, L'Aquila, Italy
| | - Chiara Di Zio
- Department of Life, Health and Environmental Sciences, University of L'Aquila, 67010 Coppito, L'Aquila, Italy
| | - Federica Matteucci
- Department of Life, Health and Environmental Sciences, University of L'Aquila, 67010 Coppito, L'Aquila, Italy
| | - Loretta Pace
- Department of Life, Health and Environmental Sciences, University of L'Aquila, 67010 Coppito, L'Aquila, Italy
| | - Maddalena Del Gallo
- Department of Life, Health and Environmental Sciences, University of L'Aquila, 67010 Coppito, L'Aquila, Italy
| |
Collapse
|
37
|
Celli M, De Giorgi U, Caroli P, Di Iorio V, Fantini L, Rossetti V, Foca F, Nicolini S, Giganti M, Paganelli G, Matteucci F. Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients. Eur J Nucl Med Mol Imaging 2020; 48:87-94. [PMID: 32588090 DOI: 10.1007/s00259-020-04914-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2020] [Accepted: 06/07/2020] [Indexed: 01/30/2023]
Abstract
PURPOSE To evaluate the clinical value of 68Ga-PSMA PET/CT negativity in patients with biochemical recurrent prostate cancer (BCR). METHODS One hundred three BCR patients (median age, 70 years; median PSA, 0.47 ng/mL) with negative 68Ga-PSMA PET/CT, followed up for at least 1 year, were retrospectively identified in a database of 1003 consecutive patients undergoing 68Ga-PSMA PET/CT for BCR. Clinical recurrence (CR) was determined or excluded on follow-up imaging selected as per clinical practice. Clinical recurrence-free survival (CRFS) was computed from the date of negative 68Ga-PSMA PET/CT to the date of evident disease; frequencies of CRFS were described as per ISUP patient subset (subset 1: ISUP grades 1 and 2; subset 2: ISUP grade 3; subset 3: ISUP grades 4 and 5) and other conventional variables. RESULTS In 57 patients out of 103 (55.3%), CR was detected in the prostatic fossa (45.6%), nodes (38.6%), and bone (15.8%). The median CRFS was 15.4 months (range, 12.1-20.5), with a CRFS at 12 months in 61.4% of cases (range, 50.9-70.4) whereas the 24-month CRFS was 34.8% (range, 24-45.8). ISUP subset 1 benefited from significantly longer CRFS compared to subset 2 and subset 3 (median CRFS, 20.5 months, 12.6 months, and 12.1 months, respectively). ISUP subset 3 had significantly poorer 24-month CRFS (9.3%) compared to subset 1 (47.8%) and subset 2 (33.5%). At the univariate and multivariate analyses, the ISUP subset was the only significant risk factor for clinical relapse; ISUP subset 3 and subset 2 patients held a higher risk of CR compared to subset 1 patients (HR of 2.75 [1.35-5.57] for subset 3 versus subset 1; HR of 2.08 [1.11-3.88] for subset 2 versus subset 1). CONCLUSION 68Ga-PSMA PET/CT negativity in early BCR patients (PSA < 0.5 ng/mL) with low-grade primary prostate cancer (ISUP1 and 2) may support the exploration of a clinical surveillance approach in future prospective studies.
Collapse
Affiliation(s)
- M Celli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - U De Giorgi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - P Caroli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - V Di Iorio
- Oncology Pharmacy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - L Fantini
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - V Rossetti
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - F Foca
- Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - S Nicolini
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - M Giganti
- Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy
| | - G Paganelli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
| | - F Matteucci
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| |
Collapse
|
38
|
Paganelli G, Sansovini M, Nicolini S, Grassi I, Ibrahim T, Amadori E, Di Iorio V, Monti M, Scarpi E, Bongiovanni A, Altini M, Urso L, Cittanti C, Matteucci F, Severi S. 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. Eur J Nucl Med Mol Imaging 2020; 48:152-160. [PMID: 32472437 DOI: 10.1007/s00259-020-04873-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2020] [Accepted: 05/18/2020] [Indexed: 12/11/2022]
Abstract
PURPOSE In March 2014, we reported the activity and safety of 177Lu-DOTA-octreotate peptide receptor radionuclide therapy (Lu-PRRT) at two different dosages (18.5 GBq and 27.5 GBq in 5 cycles) in patients with progressive metastatic gastrointestinal neuroendocrine tumors (GI-NETs). Disease control rate (DCR) and toxicity were addressed. Herein, we report the late toxicity, progression-free survival (PFS), and overall survival (OS) in the same cohort after a 10-year follow-up. METHODS We conducted an open-label, disease-oriented prospective phase II trial. From March 2008 to June 2011, 43 patients received 3.7 GBq or 5.5 GBq of Lu-PRRT every 6 to 8 weeks, each cycle repeated 5 times. All patients showed 68Gallium-DOTA-peptide PET/Octreoscan® positivity (score 3-4 Rotterdam scale) in known lesions. Tumor burden was estimated radiologically. Time-to-event data (PFS and OS) were described using Kaplan-Meier curves and compared with the log-rank test. RESULTS Forty-three patients (28 males and 15 females) were evaluable and were monitored for a median period of 118 months (range 12.6-139.6). Median PFS in patients receiving 18.5 GBq was 59.8 months (95% confidence interval [95% CI] 14.3-79.6), identical to that of patients treated with 27.5 GBq (59.8 months, 95% CI 23.4-82.0). Median OS was 71.0 months (95% CI 46.1-107.3) in the group who received 18.5 GBq and 97.6 months (95% CI 64.3-not reached) in the group treated with 27.5 GBq (P = 0.22). Patients with progression limited to lymph nodes showed significantly longer median PFS and OS than those with hepatic lesions (P = 0.02 for PFS and P = 0.04 for OS). Age over 65 years at the time of PRRT was also significant for OS. Of note, no late hematological or renal toxicity was observed in either group. CONCLUSIONS The long-term follow-up of the IRST phase II study shows that Lu-PRRT is a safe and effective therapy for patients with advanced GI-NET, the most important prognostic factor being tumor burden, hepatic lesions, and age. We believe that Lu-PRRT should be offered to patients with early-stage disease.
Collapse
Affiliation(s)
- Giovanni Paganelli
- Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Maddalena Sansovini
- Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy.
| | - Silvia Nicolini
- Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Ilaria Grassi
- Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Toni Ibrahim
- Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Elena Amadori
- Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Valentina Di Iorio
- Oncology Pharmacy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Manuela Monti
- Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Emanuela Scarpi
- Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Alberto Bongiovanni
- Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Mattia Altini
- Healthcare Administration, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Luca Urso
- Nuclear Medicine Unit, University of Ferrara, Ferrara, Italy
| | | | - Federica Matteucci
- Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Stefano Severi
- Nuclear Medicine and Radiometabolic Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| |
Collapse
|
39
|
Belli ML, Mezzenga E, Di Iorio V, Celli M, Caroli P, Canali E, Matteucci F, Tardelli E, Grassi I, Sansovini M, Nicolini S, Severi S, Cremonesi M, Ferrari M, Paganelli G, Sarnelli A. A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods. J Vis Exp 2020. [PMID: 32391816 DOI: 10.3791/60477] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
Peptide-receptor-radionuclide-therapy (PPRT) is a targeted therapy that combines a short-range energy radionuclide with a substrate with high specificity for cancer cell receptors. After injection, the radiotracer is distributed throughout the entire body, with a higher uptake in tissues where targeted receptors are overexpressed. The use of beta/gamma radionuclide emitters enables therapy imaging (beta-emission) and post-therapy imaging (gamma-emission) to be performed at the same time. Post-treatment sequential images permit absorbed dose calculation based on local uptake and wash-in/wash-out kinetics. We implemented a hybrid method that combines information derived from both 2D and 3D images. Serial whole-body images and blood samples are acquired to estimate the absorbed dose to different organs at risk and to lesions disseminated throughout the body. A single 3D-SPECT/CT image, limited to the abdominal region, overcomes projection overlap on planar images of different structures such as the intestines and kidneys. The hybrid 2D+3D-SPECT/CT method combines the effective half-life information derived from 2D planar images with the local uptake distribution derived from 3D images. We implemented this methodology to estimate the absorbed dose for patients undergoing PRRT with 177Lu-PSMA-617. The methodology could, however, be implemented with other beta-gamma radiotracers. To date, 10 patients have been enrolled into the dosimetry study with 177Lu-PSMA-617 combined with drug protectors for kidneys and salivary glands (mannitol and glutamate tablets, respectively). The median ratio between kidney uptake at 24 h evaluated on planar images and 3D-SPECT/CT is 0.45 (range:0.32-1.23). The comparison between hybrid and full 3D approach has been tested on one patient, resulting in a 1.6% underestimation with respect to full 3D (2D: 0.829 mGy/MBq, hybrid: 0.315 mGy/MBq, 3D: 0.320 mGy/MBq). Treatment safety has been confirmed, with a mean absorbed dose of 0.73 mGy/MBq (range:0.26-1.07) for kidneys, 0.56 mGy/MBq (0.33-2.63) for the parotid glands and 0.63 mGy/MBq (0.23-1.20) for submandibular glands, values in accordance with previously published data.
Collapse
Affiliation(s)
- Maria Luisa Belli
- Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy;
| | - Emilio Mezzenga
- Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Valentina Di Iorio
- Oncology Pharmacy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Monica Celli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Paola Caroli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Elisabeth Canali
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Federica Matteucci
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Elisa Tardelli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Ilaria Grassi
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Maddalena Sansovini
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Silvia Nicolini
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Stefano Severi
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Marta Cremonesi
- Radiation Research Unit, Istituto Europeo di Oncologia (IEO) IRCCS, Milano, Italy
| | - Mahila Ferrari
- Medical Physics Unit, Istituto Europeo di Oncologia (IEO) IRCCS, Milano, Italy
| | - Giovanni Paganelli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Anna Sarnelli
- Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| |
Collapse
|
40
|
Oprea A, Gunsing F, Schillebeeckx P, Aberle O, Bacak M, Berthoumieux E, Cano-Ott D, Diakaki M, Dupont E, Geslot B, Glodariu T, Heyse J, Mendoza E, Negret A, Alcayne V, Amaducci S, Andrzejewski J, Audouin L, Bécares V, Babiano-Suarez V, Barbagallo M, Becčvář F, Bellia G, Billowes J, Bosnar D, Brown A, Busso M, Caamaño M, Caballero-Ontanaya L, Calviño F, Calviani M, Casanovas A, Cerutti F, Chen YH, Chiaveri E, Colonna N, Cortés G, Cortés-Giraldo MA, Cosentino L, Cristallo S, Damone LA, Dietz M, Domingo-Pardo C, Dressler R, Durán I, Eleme Z, Femández-Domínguez B, Ferrari A, Finocchiaro P, Furman V, Göbel K, Garg R, Gawlik A, Gilardoni S, Goncalves IF, González-Romero E, Guerrero C, Harada H, Heinitz S, Jenkins DG, Jericha E, Käppeler F, Kadi Y, Kimura A, Kivel N, Kokkoris M, Kopatch Y, Krtička M, Kurtulgil D, Ladarescu I, Lederer-Woods C, Lerendegui-Marco J, Meo SL, Lonsdale SJ, Macina D, Manna A, Martínez T, Masi A, Massimi C, Mastinu P, Mastromarco M, Matteucci F, Maugeri EA, Mazzone A, Mengoni A, Michalopoulou V, Milazzo PM, Mingrone F, Musumarra A, Nolte R, Ogállar F, Patronis N, Pavlik A, Perkowski J, Persanti L, Porras I, Praena J, Quesada JM, Radeck D, Ramos-Doval D, Reifarth R, Rochman D, Rubbia C, Sabaté-Gilarte M, Saxena A, Schumann D, Smith AG, Sosnin NV, Stamatopoulos A, Tagliente G, Tain JL, Talip T, Tarifeño-Saldivia A, Tassan-Got L, Torres-Sánchez P, Tsinganis A, Ulrich J, Urlass S, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Wallner A, Woods PJ, Wright T, Žugec P. Neutron capture cross section measurements of 241Am at the n_TOF facility. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023901009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Neutron capture on 241Am plays an important role in the nuclear energy production and also provides valuable information for the improvement of nuclear models and the statistical interpretation of the nuclear properties. A new experiment to measure the 241Am(n, γ) cross section in the thermal region and the first few resonances below 10 eV has been carried out at EAR2 of the n_TOF facility at CERN. Three neutron-insensitive C6D6 detectors have been used to measure the neutron-capture gamma cascade as a function of the neutron time of flight, and then deduce the neutron capture yield. Preliminary results will be presented and compared with previously obtained results at the same facility in EAR1. In EAR1 the gamma-ray background at thermal energies was about 90% of the signal while in EAR2 is up to a 25 factor much more favorable signal to noise ratio. We also extended the low energy limit down to subthermal energies. This measurement will allow a comparison with neutron capture measurements conducted at reactors and using a different experimental technique.
Collapse
|
41
|
Mendoza E, Alcayne V, Cano-Ott D, Kimura A, Skarbeli AV, Aberle O, Amaducci S, Andrzejewski J, Audouin L, Babiano-Suarez V, Bacak M, Barbagallo M, Bécares V, Bečvář F, Bellia G, Berthoumieux E, Billowes J, Bosnar D, Brown AS, Busso M, Caamaño M, Caballero L, Calviani M, Calviño F, Casanovas A, Cerutti F, Chen YH, Chiaveri E, Colonna N, Cortés GP, Cortés-Giraldo MA, Cosentino L, Cristallo S, Damone LA, Diakaki M, Dietz M, Domingo-Pardo C, Dressler R, Dupont E, Durán I, Eleme Z, Fernández-Domíngez B, Ferrari A, Ferro-Gonçalves I, Finocchiaro P, Furman V, Garg R, Gawlik A, Gilardoni S, Glodariu T, Göbel K, González-Romero E, Guerrero C, Gunsing F, Heinitz S, Heyse J, Jenkins DG, Jericha E, Kadi Y, Käppeler F, Kivel N, Kokkoris M, Kopatch Y, Krtička M, Kurtulgil D, Ladarescu I, Lederer-Woods C, Lerendegui-Marco J, Meo SL, Lonsdale SJ, Macina D, Manna A, Martínez T, Masi A, Massimi C, Mastinu PF, Mastromarco M, Matteucci F, Maugeri E, Mazzone A, Mengoni A, Michalopoulou V, Milazzo PM, Mingrone F, Musumarra A, Negret A, Nolte R, Ogállar F, Oprea A, Patronis N, Pavlik A, Perkowski J, Piersanti L, Porras I, Praena J, Quesada JM, Radeck D, Doval DR, Reifarth R, Rochman D, Rubbia C, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schumann D, Smith AG, Sosnin N, Stamatopoulos A, Tagliente G, Tain JL, Talip Z, Tarifeño-Saldivia AE, Tassan-Got L, Torres-Sánchez P, Tsinganis A, Ulrich J, Urlass S, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Wallner A, Woods PJ, Wright TJ, Žugec P. Study of photon strength functions of 241Pu and 245Cm from neutron capture measurements. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023901015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
We have measured theγ-rays following neutron capture on240Pu and244Cm at the n_TOF facility at CERN with the Total Absorption Calorimeter (TAC) and with C6D6 organic scintillators. The TAC is made of 40 BaF2 crystals operating in coincidence and covering almost the entire solid angle. This allows to obtain information concerning the energy spectra and the multiplicity of the measured captureγ-ray cascades. Additional information is also obtained from the C6D6 detectors. We have analyzed the measured data in order to draw conclusions about the Photon Strength Functions (PSFs) of241Pu and245Cm below their neutron separation energies. The analysis has been performed by fitting the PSFs to the experimental results, using the differential evolution method, in order to find neutron capture cascades capable of reproducing at the same time a great variety of deposited energy spectra.
Collapse
|
42
|
Lerendegui-Marco J, Guerrero C, Mendoza E, Quesada JM, Eberhardt K, Junghans A, Krtiička M, Belgya T, Maróti B, Aberle O, Andrzejewski J, Audouin L, Bécares V, Bacak M, Balibrea J, Barbagallo M, Barros S, Bečvář F, Beinrucker C, Berthoumieux E, Billowes J, Bosnar D, Brugger M, Caamaño M, Calviño F, Calviani M, Cano-Ott D, Cardella R, Casanovas A, Castelluccio DM, Cerutti F, Chen YH, Chiaveri E, Colonna N, Cortés G, Cortés-Giraldo MA, Cosentino L, Damone LA, Diakaki M, Domingo-Pardo C, Dressler R, Dupont E, Durán I, Fernández-Domínguez B, Ferrari A, Ferreira P, Finocchiaro P, Furman V, Göbel K, García AR, Gawlik A, Glodariu T, Gonçalves IF, González-Romero E, Goverdovski A, Griesmayer E, Gunsing F, Harada H, Heftrich T, Heinitz S, Heyse J, Jenkins DG, Jericha E, Käppeler F, Kadi Y, Katabuchi T, Kavrigin P, Ketlerov V, Khryachkov V, Kimura A, Kivel N, Knapova I, Kokkoris M, Leal-Cidoncha E, Lederer C, Leeb H, Lo Meo S, Lonsdale SJ, Losito R, Macina D, Marganiec J, Martínez T, Massimi C, Mastinu P, Mastromarco M, Matteucci F, Maugeri EA, Mengoni A, Milazzo PM, Mingrone F, Mirea M, Montesano S, Musumarra A, Nolte R, Oprea A, Patronis N, Pavlik A, Perkowski J, Porras JI, Praena J, Rajeev K, Rauscher T, Reifarth R, Riego-Perez A, Rout PC, Rubbia C, Ryan JA, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schmidt S, Schumann D, Sedyshev P, Smith AG, Stamatopoulos A, Tagliente G, Tain JL, Tarifeño-Saldivia A, Tassan-Got L, Tsinganis A, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vescovi D, Vlachoudis V, Vlastou R, Wallner A, Warren S, Weigand M, Weiss C, Wolf C, Woods PJ, Wright T, Žugec P. Measurement of the 242Pu(n, γ) cross section from thermal to 500 keV at the Budapest research reactor and CERN n_TOF-EAR1 facilities. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023901019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The design and operation of innovative nuclear systems requires a better knowledge of the capture and fission cross sections of the Pu isotopes. For the case of capture on 242Pu, a reduction of the uncertainty in the fast region down to 8-12% is required. Moreover, aiming at improving the evaluation of the fast energy range in terms of average parameters, the OECD NEA High Priority Request List (HPRL) requests high-resolution capture measurements with improved accuracy below 2 keV. The current uncertainties also affect the thermal point, where previous experiments deviate from each other by 20%. A fruitful collaboration betwen JGU Mainz and HZ Dresden-Rossendorf within the EC CHANDA project resulted in a 242Pu sample consisting of a stack of seven fission-like targets making a total of 95(4) mg of 242Pu electrodeposited on thin (11.5 μm) aluminum backings. This contribution presents the results of a set of measurements of the 242Pu(n, γ) cross section from thermal to 500 keV combining different neutron beams and techniques. The thermal point was determined at the Budapest Research Reactor by means of Neutron Activation Analysis and Prompt Gamma Analysis, and the resolved (1 eV - 4 keV) and unresolved (1 - 500 keV) resonance regions were measured using a set of four Total Energy detectors at the CERN n_TOF-EAR1.
Collapse
|
43
|
Alcayne V, Mendoza E, Cano-Ott D, Kimura A, Aberle O, Amaducci S, Andrzejewski J, Audouin L, Babiano-Suarez V, Bacak M, Barbagallo M, Bécares V, Bečvář F, Bellia G, Berthoumieux E, Billowes J, Bosnar D, Brown AS, Busso M, Caamaño M, Caballero L, Calviani M, Calviño F, Casanovas A, Cerutti F, Chen YH, Chiaveri E, Colonna N, Cortés GP, Cortés-Giraldo MA, Cosentino L, Cristallo S, Damone LA, Diakaki M, Dietz M, Domingo-Pardo C, Dressler R, Dupont E, Durán I, Eleme Z, Fernández-Domíngez B, Ferrari A, Ferro-Gonçalves I, Finocchiaro P, Furman V, Garg R, Gawlik A, Gilardoni S, Glodariu T, Göbel K, González-Romero E, Guerrero C, Gunsing F, Heinitz S, Heyse J, Jenkins DG, Jericha E, Kadi Y, Käppeler F, Kivel N, Kokkoris M, Kopatch Y, Krtička M, Kurtulgil D, Ladarescu I, Lederer-Woods C, Lerendegui-Marco J, Lo Meo S, Lonsdale SJ, Macina D, Manna A, Martínez T, Masi A, Massimi C, Mastinu PF, Mastromarco M, Matteucci F, Maugeri E, Mazzone A, Mengoni A, Michalopoulou V, Milazzo PM, Mingrone F, Musumarra A, Negret A, Nolte R, Ogállar F, Oprea A, Patronis N, Pavlik A, Perkowski J, Piersanti L, Porras I, Praena J, Quesada JM, Radeck D, Ramos Doval D, Reifarth R, Rochman D, Rubbia C, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schumann D, Smith AG, Sosnin N, Stamatopoulos A, Tagliente G, Tain JL, Talip Z, Tarifeño-Saldivia AE, Tassan-Got L, Torres-Sánchez P, Tsinganis A, Ulrich J, Urlass S, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Wallner A, Woods PJ, Wright TJ, Žugec P. Measurement of the 244Cm capture cross sections at both CERN n_TOF experimental areas. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202023901034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Accurate neutron capture cross section data for minor actinides (MAs) are required to estimate the production and transmutation rates of MAs in light water reactors with a high burnup, critical fast reactors like Gen-IV systems and other innovative reactor systems such as accelerator driven systems (ADS). Capture reactions of244Cm open the path for the formation of heavier Cm isotopes and of heavier elements such as Bk and Cf. In addition,244Cm shares nearly 50% of the total actinide decay heat in irradiated reactor fuels with a high burnup, even after three years of cooling.Experimental data for this isotope are very scarce due to the difficulties of providing isotopically enriched samples and because the high intrinsic activity of the samples requires the use of neutron facilities with high instantaneous flux. The only two previous experimental data sets for this neutron capture cross section have been obtained in 1969 using a nuclear explosion and, more recently, at J-PARC in 2010. The neutron capture cross sections have been measured at n_TOF with the same samples that the previous experiments in J-PARC. The samples were measured at n_TOF Experimental Area 2 (EAR-2) with three C6D6detectors and also in Experimental Area 1 (EAR-1) with the Total Absorption Calorimeter (TAC). Preliminary results assessing the quality and limitations of these new experimental datasets are presented for the experiments in both areas. Preliminary yields of both measurements will be compared with evaluated libraries for the first time.
Collapse
|
44
|
Conteduca V, Scarpi E, Matteucci F, Caroli P, Ravaglia G, Fantini L, Gurioli G, Schepisi G, Wetterskog D, Menna C, Burgio SL, Lolli C, Paganelli G, Attard G, De Giorgi U. Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. JCO Precis Oncol 2019; 3:1-13. [DOI: 10.1200/po.18.00302] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
PURPOSE Biomarkers for treatment personalization in metastatic castration-resistant prostate cancer (mCRPC) could help improve patient outcomes. Multiple tests on blood have reported associations with poorer outcome, including serum lactate dehydrogenase (LDH), chromogranin A (CGA), neutrophil:lymphocyte ratio (NLR), and, recently, copy number (CN) of androgen receptor (AR) in plasma DNA. Biologic data suggest an association between choline uptake and AR signaling. We aimed to integrate 18F-fluorocholine (FCH) uptake on positron emission tomography/computed tomography (PET/CT) scanning with plasma AR CN and other routinely obtained circulating biomarkers to evaluate their association with outcome. MATERIALS AND METHODS We determined plasma AR CN by digital droplet polymerase chain reaction from 105 mCRPC samples collected before abiraterone (n = 65) or enzalutamide (n = 40) therapy in the before (n = 26) and after (n = 79) chemotherapy settings. Pretreatment serum LDH, CGA, and NLR were also measured. FCH-PET/CT scan was performed at baseline, and maximum standardized uptake value (SUVmax), total lesion activity (TLA), and metabolic tumor volume (MTV) were calculated. Main end points were the correlation of FCH-PET/CT parameters with circulating biomarkers and their impact on outcome. RESULTS Plasma AR CN gain was observed in 27 patients (25.7%), and it correlated significantly with higher median SUVmax, TLA, and MTV values ( P < .001). Kaplan-Meier curves showed significantly worse progression-free survival and overall survival in patients with plasma AR gain and higher SUVmax, TLA, and MTV values ( P < .001 in each prognostic group). Conversely, no association was reported for prostate-specific antigen response. On multivariable analysis of overall survival, we showed as independent factors AR gain (hazard ratio [HR], 1.92; 95% CI, 1.07 to 3.47; P = .029), presence of visceral metastasis (HR, 3.04; 95% CI, 1.66 to 5.58; P = < .001), LDH (HR, 2.95; 95% CI, 1.72 to 5.05; P < .001), NLR (HR, 3.51; 95% CI, 2.14 to 5.74; P < .001), serum CGA (HR, 3.36; 95% CI, 1.99 to 5.67; P < .001), and MTV (HR, 2.09; 95% CI, 1.25 to 3.50; P = .005). CONCLUSION Our results indicate the potential usefulness of integrating functional imaging with plasma DNA analysis and other noninvasive biomarkers as a tool to improve treatment selection for CRPC. A larger prospective evaluation is warranted.
Collapse
Affiliation(s)
- Vincenza Conteduca
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Emanuela Scarpi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Federica Matteucci
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Paola Caroli
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Giorgia Ravaglia
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Lorenzo Fantini
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Giorgia Gurioli
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Giuseppe Schepisi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | | | - Cecilia Menna
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Salvatore Luca Burgio
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Cristian Lolli
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Giovanni Paganelli
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | | | - Ugo De Giorgi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| |
Collapse
|
45
|
Matteucci F, Solinas L, Turri V, Donati C, D'errico V, Moretti A, Bianchini D, Paganelli G, Gallegati D, Altini M. IntegoTM infusion system: cost effectiveness analysis focusing on dosimetry, sterility and management. Q J Nucl Med Mol Imaging 2019; 63:183-190. [PMID: 27387379 DOI: 10.23736/s1824-4785.16.02866-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
BACKGROUND Healthcare providers across Europe are facing an ever-growing demand in clinical PET referrals. Currently, it is estimated that the administration of the PET tracer accounts for approximately 40% of the unitary PET procedure reimbursement (uPETr). Although the cost of PET/CT is highly dependent on the radiopharmaceutical cost itself, little is known about the economic impact of the utilized administration method and the repercussions on staff radiation exposure. Our objective was to evaluate the cost-effectiveness of automatic injection/fractionation system Intego™ (Bayer HealthCare, MEDRAD Europe, Netherlands) for istaff radiation exposure reduction and to validate its use with 18F-choline (FCH). METHODS In order to validate Intego™ use with FCH we analyzed sterility, radioactivity fractionation accuracy and radiation protection for staff. We analyzed Intego™ impact on examination costs and its impact on organization efficiency. A cost-effectiveness analysis (CEA) was estimated as the incremental cost to reduce staff radiationexposure. RESULTS According to our data, Intego™ ensures both sterility and accuracy of FCH doses' activity, reducing, at the same time, the exposure to radiation either whole body and at the extremities (94% and 75% respectively for the technicians and complete reduction for physicians). Intego™'s variable unit costs are higher than the SA (respectively 1.8% and 0.4% of PET reimbursement), while staff costs are significantly higher with SA (respectively 0.27% and 1.57% of unitary PET reimbursement [uPETr]). In our simulation, based on a 2,450 PET yearly output, the differential costs were slightly higher by using Intego™™ (+ 14%). The incremental cost-effectiveness ratio (ICER) was equal to 1.1, i.e. the healthcare provider pays an additional cost of 0.38% of uPETr to obtain a significant reduction of staff radiation exposure (-4.5 µS). CONCLUSIONS Intego™, for its favorable results in terms of cost effectiveness, could be a useful tool in a nuclear medicine department, limiting the staff radiation exposure.
Collapse
Affiliation(s)
- Federica Matteucci
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy -
| | - Laura Solinas
- Planning and Control Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Valentina Turri
- Health Care Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Caterina Donati
- Pharmacy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Vincenzo D'errico
- Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Andrea Moretti
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - David Bianchini
- Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Giovanni Paganelli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Davide Gallegati
- Planning and Control Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Mattia Altini
- Health Care Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| |
Collapse
|
46
|
De Giorgi U, Severi S, Sarnelli A, Sansovini M, Monti M, Gurioli G, Nicolini S, Scarpi E, Casadei C, Conteduca V, Matteucci F, Di Iorio V, Amadori D, Paganelli G. Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.3020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3020 Background: Plasma AR gain is associated with poor prognosis in mCRPC pts treated with abiraterone/enzalutamide, however these pts could benefit from docetaxel (Conteduca et al, Eur Urol 2019). In a phase 2 clinical trial with 177Lu-PSMA-617 in mCRPC pts who progressed after standard survival-prolonging treatments, we aimed to determine if plasma AR gene status enable early assessment of 177Lu-PSMA-617 activity for mCRPC. Methods: Between April 2017 and November 2018, 43 mCRPC pts were treated with 177Lu-PSMA-617 in a phase 2 study. Pts younger than 75 years and not heavily pretreated received 5.5 GBq of 177Lu-PSMA-617, while other pts received 4.2 GBq per cycle, for a total of 4-6 cycles, q8 weeks. We determined AR copy number by droplet digital polymerase chain reaction (ddPCR) on pretreatment plasma samples. We evaluated associations between plasma AR amplification and PSA response (≥50% PSA decline from baseline) and imaging response/progression (as measured by bone scan, CT, and PSMA PET/CT). Logistic regression was used to estimate the odds ratio (OR) and 95% confidence intervals (95% CI) in order to evaluate the independent relevance of AR status and pts without PSA response and those with early progressive disease defined as treatment interruption occurring within 4 months of the start of 177Lu-PSMA-617. Results: Forty of 43 pts (median age: 72 years, range 54-86) were fully evaluable for this analysis. A PSA response was reported in 15 (37.5%) of the 40 pts, 3 of 15 (20%) with AR gene gain, and 12 of 25 (48%) with no gain (P = 0.080). Early progressive disease was observed in 17 (42.5%) of the 40 pts, 12 of 15 (80%) with AR gene gain and 5 of 25 (20%) with no gain (P = 0.0002). The OR for pts without PSA response (decline < 50%) having AR gain was 3.69, 95% CI 0.83-16.36, p = 0.085. The OR for pts with early PD having AR gain was 16.00, 95% CI 3.23-79.27, p = 0.0007. The evaluation of germline alterations in DNA damage repair (DDR) genes is ongoing (i.e., BRCA2, BRCA1, ATM). Conclusions: Plasma AR status assessment using ddPCR identifies mCRPC resistant to 177Lu-PSMA-617. These data suggest potential better activity of 177Lu-PSMA-617 in earlier phases of prostate cancer. Prospective evaluation of treatment decision making based on plasma AR status is warranted. Clinical trial information: NCT03454750.
Collapse
Affiliation(s)
- Ugo De Giorgi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Stefano Severi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | | | - Maddalena Sansovini
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Manuela Monti
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy
| | - Giorgia Gurioli
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Silvia Nicolini
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl-IRCCS, Meldola, Italy
| | - Emanuela Scarpi
- Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Chiara Casadei
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Vincenza Conteduca
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy
| | - Federica Matteucci
- IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
| | | | - Dino Amadori
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | | |
Collapse
|
47
|
Bongiovanni A, Recine F, Fausti V, Foca F, Casadei R, Falasconi MC, Oboldi D, Sansoni E, Fabbri L, Micheletti S, Severi S, Matteucci F, Zavoiu V, Mercatali L, Amadori D, Ibrahim T. Ten-year experience of the multidisciplinary Osteoncology Center. Support Care Cancer 2019; 27:3395-3402. [PMID: 30649614 DOI: 10.1007/s00520-019-4635-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Accepted: 01/07/2019] [Indexed: 11/24/2022]
Abstract
PURPOSE Bone metastases (BMs) are responsible for high morbidity in patients. A multidisciplinary approach involving a team of specialists offers an effective therapeutic strategy based on disease characteristics, medical history, and performance status. We evaluated the impact of our 10-year multidisciplinary experience on the management of patients with BM. METHODS We retrospectively analyzed 2194 medical reports of 1628 patients referred to our Osteoncology Center from 2005 to 2015. Cases were discussed weekly by a multidisciplinary team. RESULTS Eight hundred thirty-eight (38.2%) of the 2194 visits were requested because of a risk of complications from BM. Antiblastic treatment and bone-targeted therapy were modified in 709 (66.3%) and 309 (31%) of cases, respectively. Radiotherapy was scheduled in 220 (20%) of the 1099 patients for whom information was recorded. Patients completed the Brief Pain Inventory (BPI) during their first visit, 1296 (59.1%) reporting pain (median intensity 4), and 537 (41.4%) experiencing a level that interfered substantially with daily activities. New ortheses and/or antalgic therapy was prescribed accordingly. After 7 days, 208 (16%) patients were re-evaluated and a new BPI administered. A significant improvement in the worst (p < 0.0001) and current pain (p = 0.03) was seen, together with a favorable impact on daily activities (p = 0.02). Two thousand fifty-one patients completed an anonymous questionnaire on the quality of the service, the majority (69.4%) expressing high satisfaction. CONCLUSIONS Our 10-year osteoncology experience confirms the importance of a multidisciplinary approach to optimize BM management. Further evaluations are needed in relation to quality of life, outcome, and costs.
Collapse
Affiliation(s)
- Alberto Bongiovanni
- Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy.
| | - Federica Recine
- Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Valentina Fausti
- Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Flavia Foca
- Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Roberto Casadei
- Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Maria Cristina Falasconi
- Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Devil Oboldi
- Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Elisabetta Sansoni
- Palliative Care Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Laura Fabbri
- Palliative Care Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Simona Micheletti
- Radiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Stefano Severi
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Federica Matteucci
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Venetia Zavoiu
- Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Laura Mercatali
- Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Dino Amadori
- Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| | - Toni Ibrahim
- Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy
| |
Collapse
|
48
|
Bazzani A, D'Ambrosio R, Freguglia P, Venturino E, Del Gallo M, Ercole C, Matteucci F. Dynamical model for sympatric speciation in an ecological niche. Theor Biol Forum 2019; 112:13-22. [PMID: 32125348 DOI: 10.19272/201911402002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The speciation phenomenon is the process used by the evolution to allow populations to become distinct species. The speciation is the primary cause of the complexity of the ecological network. Sympatric speciation concerns the rise of a new species from a surviving ancestral species while both continue to inhabit the same ecological niche or geographical region. In sympatric speciation, reproductive isolation evolves within a population in an ecological niche without the aid of geographic barriers. Different models have been proposed for alternative modes of sympatric speciation. The most popular was first put forward by John Maynard Smith in 1966 who suggested that in a given population homozygous individuals may, under particular environmental conditions, have a greater fitness than those with alleles heterozygous for a certain trait, eventually leading to speciation in the population. In this framework we assume an effective description of the speciation process based on a dynamical model for the populations in an ecological system. Our basic assumption is the existence of an ancestral population in an ecological niche that can express two phenotypes. In presence of certain environmental conditions one of the phenotypes has the propensity to separate from the original population in the reproduction process. Then new individuals may give rise to a new species in the ecosystem realizing a sympatric speciation. Due to the finite resources in the niche the populations are continuously competing each other's, and their numerousness fluctuates according to the changes of the environmental conditions. The effect of natural selection is introduced in the model by stochastic perturbations, that decrease the reproduction rate of the populations in the niche. We show some the dynamical properties of the system and we prove the existence of a threshold values in the environmental stress in order to observe the speciation process. We also discuss some biological implications of the model and the validation problem using empirical data.
Collapse
Affiliation(s)
- Armando Bazzani
- Dept. of Physics and Astronomy, University of Bologna and INFN sezione di Bologna
| | | | | | - Ezio Venturino
- Dept. of Mathematics 'Giuseppe Peano', University of Torino
| | | | - Claudia Ercole
- Dept. of Life, Health and Environmental Sciences, University of L'Aquila
| | - Federica Matteucci
- Dept. of Life, Health and Environmental Sciences, University of L'Aquila
| |
Collapse
|
49
|
Alcayne V, Kimura A, Mendoza E, Cano-Ott D, Martínez T, Aberle O, Andrzejewski J, Audouin L, Bécares V, Bacak M, Barbagallo M, Becčvář F, Bellia G, Berthoumieux E, Billowes J, Bosnar D, Brown A, Busso M, Caamaño M, Caballero-Ontanaya L, Calviño F, Calviani M, Casanovas A, Cerutti F, Chen YH, Chiaveri E, Colonna N, Cortés G, Cortés-Giraldo MA, Cosentino L, Cristallo S, Damone LA, Diakaki M, Dietz M, Domingo-Pardo C, Dressler R, Dupont E, Durán I, Eleme Z, Fernández-Domínguez B, Ferrari A, Finocchiaro P, Furman V, Göbel K, Gawlik A, Gilardoni S, Glodariu T, Gonçalves IF, González-Romero E, Guerrero C, Gunsing F, Harada H, Heinitz S, Heyse J, Jenkins DG, Käppeler F, Kadi Y, Katabuchi T, Kivel N, Knapova I, Kokkoris M, Kopatch Y, Krtička M, Kurtulgil D, Ladarescu I, Lederer-Woods C, Lerendegui-Marco J, Meo SL, Lonsdale SJ, Macina D, Manna A, Masi A, Massimi C, Mastinu P, Mastromarco M, Matteucci F, Maugeri EA, Mazzone A, Mengoni A, Michalopoulou V, Milazzo PM, Mingrone F, Musumarra A, Negret A, Nolte R, Ogállar F, Oprea A, Patronis N, Pavlik A, Perkowski J, Persanti L, Porras I, Praena J, Quesada JM, Radeck D, Ramos-Doval D, Rauscher T, Reifarth R, Rochman D, Sabaté-Gilarte M, Saxena A, Schillebeeckx P, Schumann D, Simone S, Smith AG, Sosnin NV, Stamatopoulos A, Tagliente G, Tain JL, Talip T, Tarifeño-Saldivia A, Tassan-Got L, Tsinganis A, Ulrich J, Urlass S, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vescovi D, Vlachoudis V, Vlastou R, Wallner A, Woods PJ, Wright T, Žugec P. Measurement of the 244Cm and 246Cm neutron-induced capture cross sections at the n_TOF facility. EPJ Web Conf 2019. [DOI: 10.1051/epjconf/201921103008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The neutron capture reactions of the 244Cm and 246Cm isotopes open the path for the formation of heavier Cm isotopes and heavier elements such as Bk and Cf in a nuclear reactor. In addition, both isotopes belong to the minor actinides with a large contribution to the decay heat and to the neutron emission in irradiated fuels. There are only two previous 244Cm and 246Cm capture cross section measurements: one in 1969 using a nuclear explosion [1] and the most recent data measured at J-PARC in 2010 [2]. The data for both isotopes are very scarce due to the difficulties in performing the measurements: high intrinsic activity of the samples and limited facilities capable of providing isotopically enriched samples.
We have measured both neutron capture cross sections at the n_TOF Experimental Area 2 (EAR-2) with three C6 D6 detectors and also at Area 1 (EAR-1) with the TAC. Preliminary results assessing the quality and limitations (back-ground subtraction, measurement technique and counting statistics) of this new experimental datasets are presented and discussed.
Collapse
|
50
|
Bonacchi M, Luca F, Demiraj A, Prifti E, Bugetti M, Matteucci F, Parisi O, De Jong M, Johnson DM, Sani G, Gulizia MM, Gelsomino S. P2689In-situ skeletonized bilateral internal thoracic artery grafting for left coronary artery revascularization: reflections on a 20-year experience. Eur Heart J 2018; 39. [DOI: 10.1093/eurheartj/ehy565.p2689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/01/2023] Open
Affiliation(s)
- M Bonacchi
- Careggi University Hospital, Florence, Italy
| | - F Luca
- Bianchi Melacrino Morelli Hospital, Cardiology, Reggio Calabria, Italy
| | - A Demiraj
- Cardiovascular Research Institute Maastricht (CARIM), Cardiothoracic Department, Maastricht, Netherlands
| | - E Prifti
- Cardiovascular Research Institute Maastricht (CARIM), Cardiothoracic Department, Maastricht, Netherlands
| | - M Bugetti
- Careggi University Hospital, Florence, Italy
| | - F Matteucci
- Cardiovascular Research Institute Maastricht (CARIM), Cardiothoracic Department, Maastricht, Netherlands
| | - O Parisi
- Cardiovascular Research Institute Maastricht (CARIM), Cardiothoracic Department, Maastricht, Netherlands
| | - M De Jong
- Cardiovascular Research Institute Maastricht (CARIM), Cardiothoracic Department, Maastricht, Netherlands
| | - D M Johnson
- Cardiovascular Research Institute Maastricht (CARIM), Cardiothoracic Department, Maastricht, Netherlands
| | - G Sani
- Careggi University Hospital, Florence, Italy
| | - M M Gulizia
- Garibaldi Nesima Hospital, Cardiology Complex Unit, Catania, Italy
| | - S Gelsomino
- Cardiovascular Research Institute Maastricht (CARIM), Cardiothoracic Department, Maastricht, Netherlands
| |
Collapse
|